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Many transporters are expressed at the basolateral membrane of human hepatocytes, including 
Organic Anion Transporting Polypeptide 1B1 (OATP1B1), OATP1B3, Organic Cation 
Transporter 1 (OCT1), Na+/Taurocholate Cotransporting Polypeptide (NTCP) and more. These 
transporters are part of the absorption system of the liver, which is responsible for the uptake of 
chemicals from the portal vein into hepatocytes for further metabolism and elimination. Extensive 
studies have characterized the function of these transporters, and results suggest that liver uptake 
transporters, like OATP1B3 and OATP1B1, or OATP1B3 and NTCP, have many overlapping 
substrates. Because these transporters seem to play an essential role in the protection of the body 
from xenobiotics, it is important to better understand their function and how they interact with 
each other. In this dissertation, I focused on one of these transporter, OATP1B3, as a model 
transporter to improve the understanding of liver uptake transporters. OATP1B3 is responsible 
for the uptake of many endogenous compounds like bile acids and hormones as well as 
xenobiotics, including numerous drugs. Recent studies demonstrated that some of the liver uptake 
transporters like OATP1B1, OCT1 and NTCP can form homo-oligomers. In the first specific aim, 
I evaluated the hypothesis that OATP1B3 also can form homo-oligomers. To address this aim, 
co-immunoprecipitation and proximity ligation assays of differently tagged OATP1B3 were 
performed in transiently transfected HEK293 cells. The results demonstrated that OATP1B3 
indeed can form homo-oligomers. In addition, uptake assays with wild-type and non-functional 
OATP1B3 suggested that the OATP1B3 unit in the homo-oligomers works as individual 
functional unit. Besides that, by using proximity ligation assays, the interaction between 
OATP1B3 and OATP1B1, and between OATP1B3 and NTCP was demonstrated in HEK293 
cells. Interactions between OATP1B3 and NTCP were also confirmed in frozen liver sections. In 
the second specific aim, I evaluated the hypothesis that OATP1B3 can form hetero-oligomers 
with other transporters and that these interactions can influence their expression and function. I 
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was able to extend the findings of hetero-oligomerization to include OCT1 using both 
immunoprecipitation and proximity ligation assays. Uptake assays and surface biotinylation 
experiments were performed with HEK293 cells co-expressing OATP1B3 and OCT1, OATP1B3 
and OATP1B1, or OATP1B3 and NTCP. The results demonstrated that these interactions 
between OATP1B3 and the other transporters lead to changes in both, function and expression of 
OATP1B3 in a transporter-dependent manner. In the third specific aim, I evaluated the hypothesis 
that photoaffinity labeling can be used to study the binding sites and translocation pathways of 
OATP1B3. The known OATP1B3 substrate 8-fluorescein-cAMP (8-FcA) was used to perform 
photoaffinity labeling experiments with CHO Flp-In cells stably expressing His-tagged 
OATP1B3. The results suggested that 8-FcA can label proteins but background labeling was very 
high even without UV activation. Purification of OATP1B3 was also attempted to improve 
chances for a successful follow-up mass spectrometry analysis. Although relatively pure protein 
was obtained, the low yield prevented further analysis. In summary, this dissertation reveals that 
1) OATP1B3 can from homo- and hetero-oligomers, and that the homo-oligomers of OATP1B3 
work as separate functional units; 2) hetero-oligomerization of OATP1B3 can result in changes of 
function and surface expression of OATP1B3 in a transporter-dependent manner; 3) photoaffinity 
labeling may be a good method to study the binding sites of OATP1B3, after the purification 
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I. Membrane transporters 
Membrane transporters are proteins expressed at the cell membrane and facilitate the transport of 
chemicals and macromolecules in and out of the cells.  Since cell membranes consist of a lipid 
bilayer which only allows certain compounds with distinct physiochemical specificities to 
penetrate freely, transporters are required for cells to take up or efflux the majority of large and 
hydrophilic endo- and xenobiotics.  The function of some ubiquitously expressed transporters is 
required for all cell types.  For example, the Na+/K+ ATPase is involved in establishing and 
maintaining of electric-chemical gradients across the cell membranes.  In contrast, the expression 
and function of other transporters are unique to certain cell types and such a distinct expression of 
transporters in only certain cell types also determines what kinds of chemicals can enter or exit 
these cells. 
Transporters can be divided into passive and active transporters based on their energy (Koegh et 
al., 2016).  Passive transporters move substrates along electrochemical gradients, while active 
transporters transfer their substrates against the gradients and consume energy.  Based on how 
they consume energy, active transporters are divided into two groups:  primary-active transporters 
use energy directly from ATP hydrolysis, like the ATP-binding cassette (ABC) transporters and 
numerous ion pumps; secondary-active transporters operate using the electrochemical gradients 
which were established by primary active transporters.  Depending on how they use the gradients, 
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secondary-active transporters can be further classified into antiporters, like the Na+/H+ exchanger, 
or symporters like the Na+/Taurocholate Cotransporting Polypeptide (NTCP).  
Membrane transporters play an essential role not only in physiology but also in pharmacology.  
They contribute to the absorption, distribution and excretion of nutrients, signaling molecules, 
metabolic end products and drugs.  For example, the enterohepatic circulation of bile acids is 
facilitated by several transporters: NTCP mediates their uptake into hepatocytes, the Bile Salt 
Export Pump (BSEP) secretes them into bile canaliculi, the Apical Sodium-Dependent Bile Acid 
Transporter (ASBT) mediates their uptake from the intestine into the enterocytes and Organic 
Solute Transporter α/β (OSTα/β) mediates their exit across the basolateral membrane into portal 
blood (Kosters and Karpen, 2008).  Transporters are also important for drug development.  They 
are major determinants of the pharmacokinetics of numerous drugs: some uptake transporters, 
like Organic Anion Transporting Polypeptides (OATPs), affect the bioavailability of drugs 
because certain OATPs remove oral drugs by rapid uptake into hepatocytes, also called first pass 
effect. Some efflux transporters, like the Breast Cancer Resistance Protein (BCRP) or some 
Multidrug Resistance associated Proteins (MRPs) influence whether certain drugs will remain 
inside the cells (Konig et al., 2013). 
 
II. Liver uptake transporters 
The liver is the most important organ for drug absorption, distribution, metabolism and excretion.  
The polarized hepatic parenchymal cells, or hepatocytes have two types of membranes, one 
facing the plasma and other hepatocytes, called basolateral or sinusoidal membrane, and one 
facing bile ductules, called apical or canalicular membrane.  The majority of the uptake 
transporters are localized at the basolateral membrane, and are responsible for the transport of 
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nutrients and drugs cross the membrane.  The uptake of drugs into hepatocytes is also referred as 
Phase 0 metabolism, because before drugs go through Phase I and II metabolisms, mediated by 
drug metabolizing enzymes, the majority of drugs need to be transported into hepatocytes by a set 
of liver uptake transporters.  Transporters expressed at the basolateral membrane of hepatocytes 
can be divided into several major families, including SLC10, SLCO, SLC22 and SLC51 (Figure 1-
1) (Hagenbuch and Stieger, 2013; Koepsell, 2013; Anwer and Stieger, 2014). 
In this part of the introduction, I will focus on the physiological, pharmacological and 
pharmaceutical perspectives of some uptake transporters and their family on the basolateral 
membrane of hepatocytes. 
 




A. The SLCO superfamily 
SLCO encodes OATP membrane transporters.  The superfamily was originally named SLC21A, 
but in 2004, the HUGO Gene Nomenclature Committee approved an amino acid sequence based 
classification system for the SLCO superfamily. A minimum of 20% identity at the amino acid 
level is required for a transporter to be assigned into a given SLC superfamily (Hediger et al., 
2013).  Within the SLCO superfamily, members with more than 40% amino acid identity belong 
to the same family. These families are numbered.  Members with more than 60% amino acid 
sequence identity belong to the same subfamily, identified with a letter alphabetically after the 
family number (Hagenbuch and Stieger, 2013).  The first human OATP, OATP1A2, was isolated 
and cloned in 1995 by the Meier group (Kullak-Ublick et al., 1995), and now over 300 OATPs 
have been identified from more than 40 species.  The mammalian transporters are classified into 6 
families (OATP1, OATP2, OATP3, OATP4, OATP5 and OATP6), and a total of 11 OATPs have 
been identified in humans (Hagenbuch and Stieger, 2013). 
Human OATPs are expressed in essentially every organ in epithelial or endothelial cells.  
Although some OATPs are expressed ubiquitously (e.g. OATP2A1, OATP3A1), others have a 
restricted distribution. For example, OATP1B1 and OATP1B3 seem to be hepatocyte specific.  
The mRNA expression levels of OATPs do not necessarily predict protein expression levels.  
This is exemplified by OATP1A2, whose mRNA can be detected in most tissues. However, at the 
protein level OATP1A2 was only detected at the blood-brain barrier, in the brush-border 
membrane in the distal nephron, in cholangiocytes, in the pars plana of the ciliary body 
epithelium, and in syncytiotrophoblasts (Hagenbuch and Stieger, 2013). 
OATPs have a broad spectrum of structurally independent substrates.  General features of OATP 
substrates are that most of them are organic anions with a molecular weight higher than 300Da.  
However, exceptions exist: some OATPs can transport organic cations and neutral compounds. 
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For example, OATP1A2 can mediate the uptake of the cationic APD-ajmalinium (Bossuyt et al., 
1996).  Conjugated and unconjugated bile acids are the most extensively studied endogenous 
substrates of OATPs.  They are substrates of OATP1A2, OATP1B1, OATP1B3, OATP2B1 and 
OATP4A1(Roth et al., 2012).  Other endogenous substrates of OATPs include thyroid hormones, 
prostaglandins, and bilirubin. 
In the human liver OATP1B1, OATP1B3 and OATP2B1 are expressed in hepatocytes, and 
OATP1A2 is expressed in cholangiocytes under normal physiological conditions. 
1) OATP1B1 
OATP1B1 was first identified and characterized in 1999, and was named as LST-1, OATP-C or 
OATP2 (Abe et al., 1999; Hsiang et al., 1999; König et al., 2000).  It has since then been 
recognized as an important transporter for the Na+-independent clearance of bile acids.  The tissue 
distribution of OATP1B1 is restricted to the human liver, and more specifically, it is located 
throughout the liver lobule evenly at the basolateral membrane of hepatocytes. 
The mRNA and protein expression of OATP1B1 is decreased in cholestatic liver disease (Zollner 
et al., 2001; Sticova et al., 2015).  Early investigations into the transcriptional regulation of 
SLCO1B1 determined that HNF1α played a predominant role.  Other nuclear transcription factor, 
like FXR can also positively affect the SLCO1B1 expression (Gui et al., 2008; Meyer Zu 
Schwabedissen et al., 2010).  At the post-translational level, activation of Protein Kinase C can 
trigger the rapid internalization and recycling of OATP1B1, and thus decrease its expression 
(Kock et al., 2010; Hong et al., 2015). 
Because OATP1B1 has a broad spectrum of structurally independent substrates, it is proposed 
that OATP1B1 has multiple translocation pathways with binding sites for the individual 
substrates.  Endogenous substrates of OATP1B1 include both conjugated and unconjugated bile 
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acids, bilirubin, conjugated estradiol, and more.  Unlike some other transporters that are mainly 
involved in the homeostasis of endogenous compounds, OATP1B1 is also very important for the 
transport of numerous xenobiotic substrates, which include various drugs, like the lipid lowering 
statins, anti-hypertensives, antibiotics, antifungals and even chemotherapeutics drugs (Table 1-1) 
(Roth et al., 2012; Hagenbuch and Stieger, 2013). 
The broad spectrum of substrates of OATP1B1 can lead to drug-drug interactions (DDIs). For 
example, the immunosuppressant cyclosporine A inhibits the uptake of several statins, resulting 
in an increased AUC and Cmax of the lipid lowering drugs when co-administered (Shitara, 2011).  
Besides DDIs, SNPs and mutations of OATP1B1 also are of significant clinical relevance.    Two 
common ethnicity-dependent polymorphisms of OATP1B1, 521 T>C and 388 A>G, which can 
lead to four distinct haplotypes, are reported to influence the AUC and Cmax of statins, affecting 
the result of statin therapies (Lee and Ho, 2016).  A rare liver disease, Rotor syndrome, is a result 
of loss of OATP1B1 and OATP1B3 function, and leads to a phenotype of hyperbilirubinemia 










Cholate Cyclosporine A 
Estradiol-17β-glucuronide Methotrexate 
Leukotriene C4 Pravastatin 























OATP1B3 was cloned and described in 2000, one year after OATP1B1 (Konig et al., 2000; Abe 
et al., 2001).  It was initially named LST-2 or OATP-8.  Further studies showed that under normal 
physiological conditions OATP1B3 is also a liver specific membrane transporter, and that it 
shares most of the OATP1B1 substrates.  However, compared to OATP1B1, OATP1B3 shows an 
increasing expression from the portal vein towards the central vein (Konig et al., 2000).   
OATP1B3 mRNA and protein were also detected in different cancer cells, such as colon, 
pancreatic and gastric cancer cell lines (Obaidat et al., 2012).  Recent studies however, showed 
that OATP1B3 expressed in cancer represents an altered splicing variant, and thus has been 
named cancer type OATP1B3 (ctOATP1B3) (Thakkar et al., 2013).  Based on this alternative 
splicing, ctOATP1B3 is missing exon 1 and part of exon 2, which results in the loss of the first 28 
amino acids.  Cancer type OATP1B3 is localized to the cytoplasm instead of to the cell 
membrane of cancer cells and has reduced transport. A recent report demonstrates that this is due 
to the missing 28 amino acids (Thakkar et al., 2013; Chun et al., 2017).   
Similar to OATP1B1, OATP1B3 function in hepatocytes is decreased by activation of Protein 
Kinase C, however without affecting protein expression in the membrane (Powell et al., 2014).  
Furthermore, the regulation of expression of OATP1B1 and OATP1B3 is not always 
synchronized.  For example, Hepatocyte growth factor (HGF) down-regulates the expression of 
OATP1B1 mRNA but not of OATP1B3 mRNA, while HNF3β only decreases the mRNA 
expression of OATP1B3 but not OATP1B1 (Vavricka et al., 2004).  Using isolated human 
hepatocytes and cell models it was demonstrated that activator of the aryl hydrocarbon receptor 
(AhR), constitutive androstane receptor (CAR), or NFE2-related factor (Nrf2) down-regulated 
OATP1B3 (Jigorel et al., 2006).  In cancer cells, OATP1B3 expression is regulated via several 
different pathways. Expression of OATP1B3 can be regulated at the epigenetic level by gene 
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silencing involving methyl-DNA binding proteins (Imai et al., 2013).  Hypoxia is also a regulator 
for the expression of OATP1B3 in cancer, and this effect is a combination of suppressing 
wtOATP1B3 and inducing ctOATP1B3 by hypoxia inducible factor-1α (HIF-1α) (Han et al., 
2013). 
Although OATP1B3 shares most substrates with OATP1B1, it has some unique substrates of its 
own, such as cholecystokinin octapeptide (CCK-8) and digoxin (Roth et al., 2012).  Besides that, 
OATP1B1 and OATP1B3 also have their own modulators and react differently to the same 
stimulators.  For example, clotrimazole inhibits the uptake of estradiol-17β-glucuronide (E17βG), 
estrone-3-sulfate (E3S) and Fluo-3 by OATP1B1, but only inhibits Fluo-3 uptake and stimulates 
E17βG uptake of by OATP1B3 (Gui et al., 2008). 
More than 40 SLCO1B3 polymorphisms have been identified, and most of them are found within 
regulatory regions like the promoter, the 5’-UTR, 3’-URT, and in introns (Boivin et al., 2010).  
However, two frequent polymorphisms, SLCO1B3-334T>G, encoding OATP1B3-S112A, and 
SLCO1B3-699G>A, encoding OATP1B3-M233I, have more than 70% allelic frequency in 
American and European Caucasians and can alter the uptake of endogenous compounds like bile 
acids, E17βG, and E3S (Letschert et al., 2004; Boivin et al., 2010).  Clinical studies also suggest 
that the polymorphism OATP1B3-M233I can influence the pharmacokinetics of digoxin in 
terminal renal failure, by increasing the concentration-to-dose ratio in hemodialysis patients 
(Tsujimoto et al., 2008).  Another study focused on chronic myeloid leukemia (CML) and 
indicated a correlation between an increased intracellular to plasma concentration ratio of 
imatinib in leukocytes and the SLCO1B3-334T>G polymorphism (Nambu et al., 2011).  
Because both OATP1B1 and OATP1B3 are involved in the uptake of numerous drugs, and can be 
modulated in a substrate-dependent way, they are of clinical relevance.  In the FDA draft 
guidance for industry regarding drug interaction studies, OATP1B1 and OATP1B3 are two of 
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seven transporters which are required to be tested for potential DDIs.  As a potential drug target 
for the uptake of anti-cancer drugs, the function of ctOATP1B3 has also been studied and it was 
shown that uptake mediated by ctOATP1B3 is only a fraction of the uptake by wild-type 
OATP1B3, suggesting the it is not a good drug target to increase anti-cancer drug uptake into 
cancer cells (Thakkar et al., 2013; Chun et al., 2017).  Although numerous reports are available 
regarding substrates and inhibitors of OATP1B3, it is still not clear how OATP1B3 and other 
OATPs facilitate the cross-membrane movement of substrates. 
The first 3D model of OATP1B3 was proposed by the Mizuguchi group in 2005 (Meier-Abt et 
al., 2005).  It is a structure-based alignment of OATP1B3 to the E. coli glycerol-3-phosphate 
transporter and lactose permease.  The study of the 3D model provided a hypothesis that 
OATP1B3, like most other transporters, has a central pseudo twofold symmetry axis, 
perpendicular to the membrane plane and a central pore.  Helices 1, 2, 4 and 5 of the N-terminal 
half and 7, 8, 10 and 11 of the C-terminal half formed the central pore, and the electrostatic 
analysis suggested that the putative pore is positively charged, which would be consistent with 
the transport of anionic substrates.  Based on this model, further studies were done to reveal the 
structure function relationship of OATP1B3 and the OATP superfamily.  Chimeras between 
OATP1B3 and OATP1B1 were used to study the OATP1B3 selective substrate CCK-8 (Gui and 
Hagenbuch, 2008).  The results demonstrated that transmembrane domain 10 (TM10) is 
important for CCK-8 selectivity of OATP1B3, and especially that amino acids Y537, S545 and 
T550 are crucial for maintaining the uptake function.  Similarly, replacing OATP1B1 amino acids 
at positions 45 in TM1, 554 in TM10 and 615 in extracellular loop 6 (ECL6) to the respective 
OATP1B3 amino acids led to an OATP1B1 with partial OATP1B3 function when measuring 
CCK-8 uptake (DeGorter et al., 2012).  Besides transmembrane domains, the putative central 
pore also drew attention for their potential function in substrate recognition.  The König group 
investigated all conserved positively charged lysine and arginine residues facing the predicted 
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central pore by site-directed mutagenesis, and showed that the positive charges at K41 and R580 
are important for the function of OATP1B3 (Glaeser et al., 2010). A similar study in our lab 
identified R57, K361 and R580 as part of the translocation pathway of OATP1B1 (Weaver and 
Hagenbuch, 2010).  Using a High-Throughput Screening Assay to identify inhibitors for 
OATP1B1 and OATP1B3, De Bruyn et al. then developed a proteochemometrics-based model to 
predict OATP1B1 and OATP1B3 inhibitors (De Bruyn et al., 2013).  They concluded that in 
order to be a potent OATP1B inhibitor compounds should have high lipophilicity and a large 
polar surface, have anionic atoms or several hydrogen bond acceptors and there should not be any 
cationic atoms present. 
3) Brief introduction to OATP2B1 and OATP1A2 
OATP2B1 and OATP1A2 are the other two members of the functionally well-characterized 
OATPs in human liver.  However, unlike OATP1B1 and OATP1B3, they are also expressed in 
other organs.  The mRNA of OATP2B1 (used to be called OATP-B) was first cloned in 2001 
from a brain cDNA library, and was subsequently detected in heart, placenta, lung, liver, kidney 
and more organs (Kullak-Ublick et al., 2001).  Protein expression of OATP2B1 was then reported 
at the basolateral membrane of hepatocytes, and other tissues, such as the intestinal epithelial 
cells, syncytiotrophoblasts in the placenta, and endothelial cells of the blood-brain barrier.  
OATP1A2 was the first human OATP and was cloned in 1995 from a liver cDNA library 
(Kullak-Ublick et al., 1995).  It was named OATP when first cloned, and the mRNA expression 
was also found in multiple organs like brain, lung, liver, kidney and testes.  Further 
characterization revealed that the liver OATP1A2 is exclusively expressed in cholangiocytes.  
Because of their wide expression in many different organs, OATP2B1 and OATP1A2 seem to 
play important roles in xenobiotic absorption, distribution and excretion. 
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Like the liver-specific OATPs, OATP2B1 and OATP1A2 have a broad substrate specificity and 
share numerous substrates with other OATPs, for example, various bile acids, E3S and some 
statins (Roth et al., 2012).  Besides general OATP substrates, OATP1A2 can also transport β-
blockers like acebutolol, while OATP2B1 is responsible for the uptake of the antidiabetic drug 
glibenclamide (Satoh et al., 2005).  Although the general driving force for OATPs is still not 
clear, extracellular pH can affect the function of OATP2B1 (Kobayashi et al., 2003; Visentin et 
al., 2012).  Two studies have shown that OATP2B1 transport activity decreased from pH 5.0 to 
7.4 (Nozawa et al., 2004), and pH 6.5 to 8.0 (Leuthold et al., 2009).  However, different 
mechanisms of pH-sensitive transport have been proposed.  The Tamai group claimed that the 
proton gradient can serve as the driving force of OAP2B1-mediated uptake, while the results of 
the Stieger group suggested that the protonation of a conserved histidine residue at ECL2 could 
increase the affinity of certain substrates to OATP2B1. 
B. The Na+/taurocholate cotransporting polypeptide (NTCP) 
NTCP belongs to the SLC10A family, which is also known as the “sodium bile salt cotransport 
family” (Hagenbuch and Dawson, 2004; Anwer and Stieger, 2014).  This transporter gene family 
has 7 members but only three members have been well characterized (SLC10A1, SLC10A2 and 
SLC10A6), and two of them (SLC10A1, encoding NTCP and SLC10A2, encoding the apical 
sodium-dependent bile salt transporter, or ASBT) are responsible for the uptake of classic bile 
acids into liver or intestine, while the other one (SLC10A6, encoding sodium-dependent organic 
anion transporter, or SOAT) is a transporter for sulfated bile acids.  As indicated in the name, 
transporters in this family are all secondary active transporters, using the sodium gradient to carry 
out their function.  NTCP and ASBT are considered as essential transporters to maintain the 
enterohepatic circulation of bile acids (Kosters and Karpen, 2008).  ASBT reabsorbs the bile 
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acids from intestine through the apical membrane of enterocytes, while NTCP takes them up from 
plasma back into liver across the basolateral membrane of hepatocytes. 
Human NTCP was first cloned in 1994, and is considered the major bile acid uptake transporter 
(Hagenbuch and Meier, 1994).  Although both NTCP and OATPs can transport bile acids, studies 
using Slco1a/1b or Slco1b2 knockout mice showed unchanged levels of conjugated bile acid 
levels but elevated levels of unconjugated bile acids in plasma, which suggest that at least in 
mice, conjugated bile acids are the main substrates of NTCP while unconjugated ones are 
substrates of OATPs (van de Steeg et al., 2010; Csanaky et al., 2011).  Other than bile acids, 
NTCP can also transport steroid hormones, thyroid hormones and drugs like statins and 
micafungin (Yanni et al., 2010).  In addition, drugs conjugated with bile acids, for example, 
chlorambucil-taurocholate (Kullak-Ublick et al., 1997), have been designed to target NTCP as the 
route to enter hepatocytes (Sievanen, 2007; Anwer and Stieger, 2014). 
High bile acid levels can activate FXR and subsequently down-regulate the mRNA expression of 
NTCP via activation of SHP and inhibition of HNF1α (Kosters and Karpen, 2008).  NTCP 
plasma membrane levels are highly regulated by several factors.  Signaling pathways including 
cAMP, intracellular Ca2+, nitric oxide, phophoinositide-3-kinase (PI3K), protein kinases and 
protein phosphatases can all influence the plasma membrane expression of NTCP (Anwer and 
Stieger, 2014).  In addition, NTCP undergoes retrieval and degradation when exposed to high 
concentrations of cholestatic bile acids, thus reducing the uptake of bile acids and protecting 
hepatocytes from further increase of intracellular bile acids in cholestasis (Keitel et al., 2005). 
Not much evidence of clinical relevance of NTCP has been shown so far.  There are only two 
studies that have demonstrated that mutations or single-nucleotide polymorphism (SNP) in NTCP 
result in hypercholanemia (Vaz et al., 2015; Deng et al., 2016).  In addition, recent studies 
described a novel important function of human NTCP (hNTCP).  hNTCP supports the binding 
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and entry of hepatitis B virus (HBV) and hepatitis D virus (HDV) into hepatocytes (Yan et al., 
2012; Tsukuda et al., 2017). Follow-up studies demonstrated that unlike hNTCP, mouse NTCP 
can only support the binding but not the entry of HBV and HDV into cells.  The van de Graaf 
group generated an NTCP knockout mouse model and further demonstrated that in Slc10a1-/- 
mice, the HBV hepatic binding was completely abrogated in vivo.  In support of these findings 
another group generated an hNTCP transgenic mouse and could restored the entry of HDV 
mediated by hNTCP (He et al., 2015).  With these useful animal models, a new class of 
chemicals, like proanthocyanidin, have been developed to inhibit the binding and entry of HBV 
and HDV by targeting NTCP (Tsukuda et al., 2017).  Besides that, an NTCP-directed inhibitor 
peptide (Myrcludex B), with an IC50 of approximately 80 pM, has also been developed and is 
currently in Phase II clinical trials (Schulze et al., 2010; Lempp and Urban, 2014). 
C. The organic cation transporter 1 (OCT1) 
OCT1 belongs to the SLC22 family, which consists of 13 functionally characterized transporter 
members in humans (Koepsell and Endou, 2004; Koepsell, 2013).  This family contains 3 
subgroups with closely related proteins, including organic cation transporters (OCTs), organic 
zwitterion/cation transporters (OCTNs) and organic anion transporters (OATs).  The OCT 
subgroup has 3 members encoded by SLC22A1-3 (OCT1-3) which transport small organic 
cations, weak bases and some neutral compounds.  OCTs are generally considered as facilitated 
diffusion systems that can mediate the transport of their substrates in both directions across the 
plasma membrane, depending on the electrochemical gradients.  The OCTN subgroup also has 3 
members, encoded by SLC22A4, SLC22A5 and SLC22A16 (OCTN1, OCTN2 and OCT6, 
respectively).  This subgroup can serve as either uniporter, antiporter or sodium-cotransporter, 
depending on the transported substrates.  The third subgroup has 9 members, encoding OAT1-7 
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and 10, and URAT1.  The substrates of the OAT subgroup are mostly organic anions, but with a 
smaller molecular weight compared to OATPs. 
Human OCT1 was first cloned in 1997 and is mainly expressed at the basolateral membrane of 
human hepatocytes (Grundemann et al., 1994).  At the protein level expression of OCT1 is 
highest in liver, but OCT1 is also detectable in the kidney at the basolateral membrane of S1 and 
S2 segments of the proximal tubules, in the lung at the luminal membrane of bronchial epithelial 
cells, in the brain in endothelial cells of microvessels and in the cornea, the iris-ciliar body and 
blood-retina barrier of the eye (Koepsell et al., 2007).  Substrates of OCT1 include endogenous 
compounds, such as the neuromodulators histidyl-proline diketopiperazine (cyclo(His-Pro)) and 
salsolinol; model cations and toxins such as tetraethylammonium (TEA) and 1-methyl-4-
phenylpyridinium (MPP); and drugs like the antidiabetic metformin, the antiviral acyclovir and 
more (Koepsell, 2013). 
Malfunction of OCT1 is not currently associated with any diseases, but large interindividual 
differences in expression of OCT1 have been observed.  Since OCT1 is a transporter for multiple 
drugs, the variability in OCT1 expression can lead to altered pharmacokinetics (Soodvilai et al., 
2017).  Besides that, many nonsynonymous SNPs have been identified, 10 of them affect the 
expression and 6 alter substrate selectivity (Koepsell et al., 2007).  Because of its multiple 
substrates, DDIs are to be expected at OCT1.  Tyrosine kinase inhibitors (TKI) including imatinib 
and gefitinib potently inhibit the uptake of metformin and could influence the clinical outcome of 
metformin treatment (Minematsu and Giacomini, 2011). 
D. Brief introduction to other SLC transporters in hepatocytes 
Besides the transporters introduced above, there are several other related uptake transporters 
expressed in human hepatocytes.  Three other members from the SLC22 family, OCT3 
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(SLC22A3), OAT2 (SLC22A7) and OAT7 (SLC22A9) are also localized at the basolateral 
membrane (Roth et al., 2012).  Compared to OCT1, OCT3 has a much wider expression range 
(Koepsell, 2013).  Strong mRNA expression of OCT3 can be detected in liver, placenta, kidney 
and skeletal muscle.  OCT3 plays an important physiological role in the CNS, where it can 
regulate the interstitial concentration of monoamine neurotransmitters and cationic drugs and thus 
control neuronal activities and behavior (Baganz et al., 2008). Because OCT3 can also transport 
many monoamines outside the CNS, it is also called “extraneuronal monoamine transporter” or 
EMT (Koepsell et al., 2007).   
  OAT2 is mainly expressed in the liver, but can also be detected in the kidney, in testis, ileum 
and uterus.  Compared to OATP substrates, substrates of OAT2 are relatively small organic 
anions including many endogenous compounds like glutamate, purine and pyrimidine 
nucleobases, nucleosides and nucleotides, drugs like salicylate, erythromycin and 5-fluorouracil.  
Unlike OATPs, the major role of OAT2 at basolateral membrane of hepatocytes is the efflux of 
glutamate into sinusoids.  OAT7 is exclusively expressed in the liver, and compared to other 
OATs it has a much narrower substrates selectivity, mainly transporting sulfate conjugates.  The 
transport mechanism of OAT7 is also unique, compared to other OATs, because it uses short-
chain fatty acids to exchange its sulfate conjugated substrates (Koepsell, 2013).   
Organic solute transporters α and β (OSTα-OSTβ, SLC51A-SLC51B) are expressed at the 
basolateral membrane of hepatocytes.  They represent one of the most unique transporters in the 
SLC family, because OSTα-OSTβ consist of the heterodimer of OSTα and OSTβ, encoded by 
SLC51A and SLC51B, respectively.  OSTα is a 340-amino acids transporter with 7 
transmembrane domains, while OSTβ has only 128 amino acids and one transmembrane domain.  
OSTα-OSTβ are expressed ubiquitously in the body, but the strongest expression is found in 
tissues involved in bile acid homeostasis like the small intestine, the kidney and the liver.  It 
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represents a multispecific transporter with substrates including bile acids, E3S, digoxin and more.  
OSTα-OSTβ is part of the transporter system to maintain the enterohepatic circulation of bile 
acids.  In enterocytes, it excretes bile acids into the portal circulation and NTCP takes them back 
up into hepatocytes across the basolateral membrane (Ballatori et al., 2013). 
E. Introduction to oligomerization of transporters 
Oligomerization of proteins is an important physiological phenomenon.  Oligomeric proteins 
contain two or more associating polypeptide chains.  From an evolutionary perspective, such 
oligomerization represents a potential advantage because protein oligomers can be controlled or 
regulated via allosteric interactions and higher-orders of complexity can be created (Ali and 
Imperiali, 2005).  Based on a survey of crystal structures, at least 50% of the proteins in a cell are 
oligomeric (Goodsell and Olson, 2000; Nishi et al., 2013).  Depending on the type of interaction, 
oligomerization of proteins results in various consequences.  Many proteins require the close 
interaction with itself or with other proteins to be functional.  For example, hemoglobin is a 
heterotetramer of two α and two β subunits, and the interaction between those subunits leads to a 
cooperative binding of oxygen.  In addition, oligomerization can lead to variations in expression 
and function or alter cell signaling (Ali and Imperiali, 2005). 
The interactions of proteins require an oligomeric interface, and in general, the residues involved 
in the interface are more hydrophobic and non-polarized compared to the other fraction of the 
protein, which will facilitate the formation of hydrophobic interactions between proteins (Ali and 
Imperiali, 2005).  These characters of oligomerization indicate that transporters and other 
membrane proteins may have a higher chance of oligomerization because of the abundance of 
hydrophobic α-helical transmembrane domains. 
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ABC transporters can be classified into “full” or “half transporters”.  Instead of having 2 
transmembrane domains (TMD) and 2 nucleotide-binding domains (NBD), the half transporter 
consists of one TMD fused to one NBD. Therefore, homo- or hetero-dimerization with another 
half transporter is required for function (Dean et al., 2001; Wilkens, 2015).  For example, Breast 
Cancer Resistance Protein (BCRP), encoded by ABCG2, forms homo-oligomers and tetrameric 
complexes (two BCRP dimers), and it has been suggested that BCRP function could be regulated 
by the dynamic association/dissociation of BCRP monomers via protein-protein interactions (Ni 
et al., 2010).  Besides interactions within the ABC family, it has also been demonstrated that 
some of the ABC transporters can oligomerize with other proteins.  P-glycoprotein (Pgp) or 
MDR1 encoded by ABCB1, is a drug efflux pump.  It is expressed in the liver, the kidney, the 
intestine and at the blood-brain barrier (BBB), and also in many cancers where it confers the 
multidrug resistance phenotype.  At the BBB, Pgp forms hetero-oligomers with caveolin-1 and 
caveolin-2, which colocalize in caveolae.  When bovine brain capillary endothelial cells were 
cultured with caveolae-disrupting agents like filipin III and nystatin, the transport activity of Pgp 
was reduced significantly, suggesting that the formation of this oligomer modulates the function 
of Pgp (Jodoin et al., 2003). 
OSTα-OSTβ, described above, are a great example of SLC transporters that form oligomers.  For 
their proper function, oligomerization of the two proteins of different sizes is required (Wang et 
al., 2001).  Another example of such hetero-oligomerization is the heteromeric amino acid 
transporters (HAT) that are formed between the light chains of the SLC7 family with one of the 
two heavy chains of the SLC3 family (Fotiadis et al., 2013). Recent studies demonstrated homo- 
and hetero-oligomerization of other SLC family members.  These interactions did not all have 
functional consequences.  OAT1 (SLC21A6) is predominantly expressed in kidney and brain and 
is responsible for the uptake of many environmental toxins.  Several studies showed that OAT1 
can form homo-oligomers (Hong et al., 2005), and when the oligomerization is interrupted by 
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either TM6 short peptide (Duan et al., 2011a) or mutations at the GXXXG motif (Duan et al., 
2011b), the surface expression of OAT1 was reduced, suggesting that the oligomerization may be 
important for the correct localization of OAT1. 
The oligomeric states of some liver transporters were also studied.  The first study was conducted 
in 2008 by the Koepsell group. They used a cell free expression system to reconstitute rat OCT1, 
OCT2 and OAT1, then solubilized them and detected the formation of rOCT1 and rOAT1 homo-
oligomers by co-immunoprecipitation (Keller et al., 2008).  Another study from the same group 
confirmed the in vivo formation of oligomers in X. laevis oocytes that were injected with rOCT1 
cRNA (Keller et al., 2011).  In the same study, the cysteine residues in ECL1 of rOCT1 were 
replaced by serine residues, and these mutations prevented the oligomerization, suggesting that 
disulfide bonds are crucial for the dimerization.  Though a decreased Km of the uptake of 
tetraethyammonium+ (TEA) by mutant rOCT1 was determined, similar substrate affinities of the 
oligomerizing and non-oligomerizing rOCT1 were obtained indicating that the altered Km was 
due to the cysteine mutation instead of the “non-oligomerization”.  A further study confirmed this 
result by showing no changes after comparing Km before and after treatment with dithiothreitol 
(Keller et al., 2011).  Combining these studies, it was concluded that rat OCT1 can form homo-
oligomers and that oligomerization does not affect the transport function. 
The oligomeric state of the first human liver transporter reported was NTCP (Bijsmans et al., 
2012).  Based on older studies and results that showed unexpected higher bands on immunoblots, 
two differently tagged NTCP proteins were generated for co-immunoprecipitation and 
fluorescence resonance energy transfer (FRET) experiments.  Indeed, the results showed that 
NTCP can form homo-oligomers.  Additional experiments demonstrated that like rat OCT1, 
NTCP homo-oligomers worked as individual subunits.  In this study, immunofluorescence 
images suggested that besides with itself, NTCP also co-localized with additional transporters of 
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the SLC10 family, P4 (SLC10A4) and SOAT (SLC10A6).  The hetero-oligomerization with P4 
influenced the expression of NTCP, and reduced the bile acid uptake function of NTCP.  Besides 
NTCP, a recent study also demonstrated the homo-oligomerization of OATP1B1, and suggested 
that the GXXXG motif at position 219 and 393 could affect expression and function of 
OATP1B1 (Ni et al., 2017). 
 
III. Photoaffinity Labeling 
A. Overview 
Photoaffinity labeling is a powerful technique for the study of protein ligand interactions.  This 
method was first introduced by Frank Westheimer in the early 1960s (Singh et al., 1962), and was 
developed and evolved continuously after then.  The rationale behind this method is to turn the 
weak binding into a solid covalent bond between the target protein and the photoreactive ligand 
(Smith and Collins, 2015).  By modifying a ligand with a photo-reactive moiety, such as a 
diazirine, arylazide or benzophenone, the ligand can be activated at the appropriate wavelength of 
light, and the reactive intermediate reacts with almost any type of amino acid close to it and forms 
a covalent bond with it (Hashimoto and Hatanaka, 2008).  After it was developed, photoaffinity 
labeling was widely applied in the field of protein interaction studies, such as ligand binding, 
protein-protein or protein-nucleic acid interactions (Smith and Collins, 2015). However, with the 
development of structural analysis techniques, such as mass spectrometry and high-performance 
liquid chromatography, scientists can now perform even more in-depth analysis after the labeling 
process (Robinette et al., 2006), and thus, currently, identifying or characterizing the ligand-
binding site within the protein has become the common application of photoaffinity labeling 
(Smith and Collins, 2015).   
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The most significant strength of photoaffinity labeling is the relative tight interaction between 
ligand and target proteins (Hashimoto and Hatanaka, 2008).  Besides that, several other benefits 
make photoaffinity labeling a good technique for protein interaction studies.  The photoreactive 
moiety is relatively small, so it can be attached to proteins, nucleic acids and even small molecule 
drugs like salicylic acid, without significantly interfering with their original structure and function 
(Tian et al., 2012).  Some small molecule ligands may be capable of intrinsic photoactivation, 
such as compounds contain sulfides, enones, dienones and halogenated moieties (Robinette et al., 
2006). Photoreactive moieties can also be attached to ligands with a fluorophore or radioactive 
ligand which can further facilitate the detection process. 
Though photoaffinity labeling is well-characterized, there are some downsides of this method.  
The design of a photoreactive probe is relative challenging.  A number of variables can affect the 
outcome of the experiment, such as the stability of the probe in the dark at a range of pHs, and the 
strength of the newly formed bond (Smith and Collins, 2015).  Besides that, the wavelength 
required to activate certain photoreactive moieties can also damage the biological molecules.  
Because of these shortcomings, the application of photoaffinity labeling is limited.  Photoaffinity 
labeling can be a good technique to study transporters.  As a membrane protein, it is relatively 
difficult to purify and crystalize a transporter, and thus, the structure information of transporters is 
very limited compared to soluble proteins.  Photoaffinity labeling provides the possibility of 
identifying binding-sites of a transporter without crystallization.  In addition, photoaffinity 
labeling may help to characterize the translocation pathways by analyzing the binding of ligands 
in the transmembrane domains. 
B. Application of Photoaffinity labeling to transporters 
The first identification and characterization of the rabbit ileum Na+-dependent bile acid 
transporter (IBAT, or rabbit ASBT) in 1993 included photoaffinity labeling and transporter 
22 
 
assays (Kramer et al., 1993).  Brush border membrane vesicles from 8 different segments in the 
small intestine were analyzed for the expression of the bile acid transport system.  A diazirine-
labeled bile acid derivative was used to screen membrane proteins which can bind bile acids.  A 
93-kDa membrane protein was identified as the potential ileal Na+-dependent bile acid transporter 
because its expression correlated in the ileum with bile acid transport and because photoaffinity 
labeling occurred only in the presence of sodium.  This protein was further investigated and 
named IBAT.  After IBAT was cloned in 1994, Kramer’s group again used photoaffinity labeling 
techniques to characterize the uptake function of IBAT by competing the binding site of the 
photoreactive bile acids with potential substrates and thus identified potential substrates or 
inhibitors of IBAT (Kramer et al., 1997; Kramer et al., 2001a). 
Photoaffinity labeling was also used to study the binding pockets of transporters like P-
glycoprotein (Pgp), also called multidrug resistance protein 1 (MDR1) (Safa, 2004).  By using 
site-directed antibodies, the binding of photoreactive substrates could be blocked and the binding 
domains could then be identified (Morris et al., 1994).  Combining studies of many different 
photoreactive substrates, the Callaghan group concluded that there are at least four binding sites 
in Pgp, which can be divided into transport sites and regulatory sites (Martin et al., 2000).  By 
mutating these binding sites that were identified by photoaffinity labeling, the mechanism of drug 
resistance by Pgp was also investigated.  Furthermore, based on photoaffinity labeling results a 
general pharmacophore was proposed for  Pgp, which contained two hydrophobic points, three 
hydrogen bond acceptor points and one hydrogen bond donor (Pajeva and Wiese, 2002). 
To conclude, photoaffinity labeling can be a powerful tool to identify and characterize the 
binding pockets of proteins.  It is widely applied in the study of protein related interactions, 
especially in the drug discovery and development processes.  The application of photoaffinity 
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labeling in the study of IBAT and Pgp has shown a great potential of using this technique to 
improve the structure function studies of transporters. 
 
IV. Concluding remarks for the introduction 
Transporters in human liver play a pivotal role in the absorption, distribution and elimination of 
numerous compounds.  Previous results have revealed the oligomeric state of some transporters 
and their potential influence on the function of transporters.  Besides that, photoaffinity labeling 
has been used as a unique technique to study the translocation mechanism of transporters.  To 
further understand liver uptake transporters, the oligomeric state and structure function 
relationship of OATP1B3 needs to be studied in order to answer the following questions: 1) Does 
OATP1B3 form homo-oligomers and what would be its functional consequence?  2) What is 
the relationship among liver transporters, do they interact and are there any functional 
consequences of such interactions?  3) How does OATP1B3 translocate its substrates? 
 
V. Specific aims of this dissertation 
The overall goal of my research was to study the oligomeric state and translocation pathways of 
OATP1B3, and the potential functional consequences. In presenting this dissertation, I will 
defend 3 specific aims. 
Specific aim 1 evaluates the hypothesis that OATP1B3 can form homo-oligomers and the 
interaction can affect the uptake function of OATP1B3.  To address this aim, two differently 
tagged OATP1B3 plasmids were constructed and were used for co-immunoprecipitation in co-
transfected HEK293 cells.  Then the proximity ligation assay was used to further confirm the 
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interaction between OATP1B3 and itself.  Uptake assays were performed to investigate potential 
functional consequences.  The purpose of this study was to investigate the oligomeric state of 
OATP1B3 and its potential functional consequences. 
Specific aim 2 evaluates the hypothesis that OATP1B3 can form hetero-oligomers and the 
interaction with other transporters can affect the expression and function of the involved 
transporters.  To investigate this aim, OATP1B3 was cotransfected into HEK293 cells with 
other transporters including OATP1B1, NTCP and OCT1, and the proximity ligation assay was 
used to detect the interaction between these transporters.  Then frozen liver sections were used to 
confirm the interaction in human liver.  After the interaction was confirmed, functional 
consequences and surface expression were studied by using cotransfected HEK293 cells.  The 
purpose of this study was to determine the interaction between liver transporters and the potential 
functional consequences. 
Specific aim 3 evaluates the hypothesis that photoaffinity labeling can be used to study the 
substrate binding sites and translocation pathways of OATP1B3.  To study this aim, a 
working method to isolate, solubilize and purify OATP1B3 from OATP1B3 stable transfected 
Chinese Hamster Ovary (CHO) cells was established.  After that, 8-fluorescein-cAMP was 
applied to intact CHO cells and UV light was used to form covalent bonds between the molecule 
and OATP1B3.  I then attempted to isolate and purify labeled OATP1B3 for mass spectrometry 






Materials and Methods 
I. Materials 
Radioactive compounds, [3H]estrone-3-sulfate (E3S, 54.0 Ci/mmol), [3H]estradiol-17β-
glucuronide (E17βG, 49.8 Ci/mmol),  [
3
H]CCK-8 (87.9 Ci/mmol) and [3H]taurocholate acid (15.4 
Ci/mmol) were purchased from PerkinElmer (Boston, MA). [
3
H]1-methyl-4-phenylpyridinium 
(MPP+) (80 Ci/mmol) was from American Radiolabeled Chemicals (St. Louis, MO), and 
[
14
C]metformin (112 mCi/mmol) was from Moraveck Biochemicals (Brea, CA). Unlabeled CCK-
8 was purchased from Bachem (Torrance, CA).  The crosslinking reagent 3,3'-dithiobis 
(sulfosuccinimidyl propionate) (DTSSP) and Dynabeads® Protein G for immunoprecipitation 
were purchased from ThermoFisher (Waltham, MA).  Duolink components for the proximity 
ligation assay were from Sigma-Aldrich (St. Louis, MO).   Mouse anti-FLAG antibody 
conjugated to magnetic beads was from Sigma-Aldrich (St. Louis, MO).  Primary antibody 
information is listed in Table 2-1.  All other chemicals and reagents were of analytical grade and 
were readily available from commercial sources. Frozen human liver was obtained through the 
Cell Isolation Core in the Department of Pharmacology, Toxicology and Therapeutics at 
University of Kansas Medical Center, in accordance with a protocol approved by the Institutional 
Review Board of the University of Kansas Medical Center from patients undergoing hepatic 









































































































































































































































































































































































































































































II. Generation of OATP1B3 with a FLAG- or HA-tag at the C-terminal end 
To generate OATP1B3 with either a C-terminal FLAG- or HA-tag, the open reading frame (ORF) 
of OATP1B3 was amplified with the following primers using the expression plasmid encoding 
the His-tagged OATP1B3 as a template: Forward, 5’ 
GCTAGCTAATACGACTCACTATAGGGACCATGGAC 3’; OATP1B3-FLAG reverse, 5’ 
GCGGCCGCTTACTTAT 
CGTCGTCATCCTTGTAATCGTTGGCAGCAGCATTGTCTTGCATGT 3’; OATP1B3-HA 
reverse, 5’ 
GCGGCCGCTTAAGCGTAATCTGGAACATCGTATGGGTAGTTGGCAGCAGCATTGTCT
TGCATGT 3’.  After amplification, the ORF of OATP1B3 with either a FLAG- or an HA-tag 
was inserted between the NheI and XhoI sites of the pcDNA5/FRT plasmid.  The resulting 
constructs were sequenced to verify insertion of the desired tags. 
 
III. Cell culture and transporter expression 
Chinese Hamster Ovary (CHO) Flp-In cells transfected with OATP1B3-His or pcDNA5/FRT 
(Empty Vector) were previously generated.  Human embryonic kidney (HEK293) cells were 
purchased from ATCC (Manassas, VA); the cells were routinely tested for the absence of 
mycoplasma using the MycoAlert™ Mycoplasma Detection Kit (Lonza, Hopkinton, MA).  CHO 
Flp-In cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) with 1 g/L D-glucose, 
2mM L-glutamine, 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer, 
and 110mg/L sodium pyruvate supplemented with 10% fetal bovine serum (FBS) (Hyclone, 
Logan, Utah), 50mg/ml L-proline, 100U.mL penicillin, 100mg/mL streptomycin (Invitrogen), 
and 500 mg/mL hygromycin (Invitrogen, Carlsbad, California) in a humidified environment at 
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37°C and 5% CO2.  HEK293 cells were grown in DMEM high glucose (Invitrogen, Carlsbad, 
CA), supplemented with 10% FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin in a 
humidified environment at 37°C and 5% CO2.  Plating, transfection and uptake experiments on 
24-well plates were performed as previously reported (Zhao et al., 2015). Transfection conditions 
varied among different experiments (for detailed conditions see figure legends) with constant 
500ng total plasmids been transfected.  The following day media was changed and uptake 
experiments (for time points see figure legends) were performed 24 or 48 hours after transfection. 
Each transfection condition was performed in triplicate. 
 
IV. DUALmembrane screening 
The DUALmembrane screening, a modified yeast two-hybrid screening, was performed by 
Dualsystems Biotech AG (Schlieren, Switzerland) with full-length OATP1B3 as the bait and a 
human adult liver cDNA library with 1.5 x 106 independent clones. 
 
V. Immunofluorescence 
Transiently transfected HEK293 cells in 4-well chambers were washed three times with 
phosphate-buffer saline (PBS) and fixed and permeabilized with 2% paraformaldehyde in PBS 
for 10 minutes in the presence or absence of 1% Triton-X 100.  After another 4 washes with PBS, 
cells were blocked with 5% normal donkey serum for 1 hour at room temperature.  Cells were 
then incubated at 4°C overnight with the respective primary antibodies in 1% normal donkey 
serum in PBS.  After washing with PBS, slides were incubated with donkey anti-mouse 
AlexaFluor 488 (ThermoFisher) as secondary antibody, diluted 1:1000 in 0.1% PBS-Tween for 1 
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hour, and after a final wash, slides were mounted in Prolong Gold containing DAPI 
(ThermoFisher).  For negative controls, the sections were incubated with secondary antibody 
only. 
 
VI. Proximity ligation assay 
Transiently transfected HEK293 cells in 8-well chambers were washed three times with PBS and 
fixed with PBS containing 2% paraformaldehyde and 1% TX-100 in PBS for 10 minutes.  After 4 
washes with PBS, cells were blocked with 5% normal donkey serum for 1 hour at room 
temperature and then incubated overnight at 4°C with respective primary antibodies (see details 
in figure legends).  After 4 washes with PBS, slides were incubated with the respective pair of 
Duolink® In Situ PLA® Probes (Sigma-Aldrich) at room temperatures for 1 hour, and then 
washed twice for 5 minutes each with Wash Buffer A (Sigma-Aldrich). Ligation at 37°C for 30 
minutes and amplification at 37°C for 100 minutes were then performed following the 
manufacturer’s protocols. Before mounting with Duolink® In Situ Mounting Medium with DAPI 
(Sigma-Aldrich), cells were washed twice for 10 minutes each with Wash Buffer B and once for 
1 minute with 0.01 x Wash Buffer B. 
 
VII. Crosslinking and isolation of membrane fractions 
Transiently transfected HEK293 cells and freshly isolated and plated human hepatocytes were 
washed with PBS and then incubated in PBS with or without 2mM DTSSP in PBS for 
crosslinking at 4°C for 2 hours.  Crosslinking was stopped by incubating with 20mM Tris-HCl 
(pH 7.5) for 15 minutes.  Cells were then washed with ice-cold PBS, and cold hypotonic 
30 
 
homogenization solution (1mM NaCl, 5mM Tris-HCl pH 7.5) with Complete Protease Inhibitor 
Cocktail (Roche Diagnostics Corporation, Indianapolis, IN) was added before cells were scraped 
off the plates.  The cells were homogenized with 20 strokes using a glass-Teflon homogenizer, 
and the homogenates were centrifuged at 900 x g for 10 minutes.  The resulting supernatants were 
centrifuged again at 10,000 x g for 20 minutes and the pellet containing a membrane enriched 
fraction was solubilized with PBS containing 0.1% NP-40. After centrifugation at 14,000 x g for 
30 minutes to remove insoluble particles, the supernatant was used for immunoprecipitation 
experiments. 
 
VIII. Protein purification by Ni-NTA columns 
Membrane enriched fractions isolated from one 10 cm dish of CHO Flp-In cells were first 
solubilized in 500 μL of Lysis Buffer (150mM NaCl, 1mM EDTA, 0.1% SDS, 1% Triton X-100, 
10mM Tris-HCl, pH=7.5) for 10 minutes on ice. After a 14,000 x g centrifugation for 30 minutes 
at 4 °C the supernatant was kept for purification and the pellet was discarded.  Ni-NTA spin 
columns (Qiagen) were equilibrated twice with 500 μL of Lysis buffer and centrifuged at 900 x g 
to remove the Lysis Buffer.  The supernatants were then loaded on to the columns and spun down 
at 300 x g to bind the 6 x His-tagged proteins.  After binding, columns were washed twice with 
Lysis Buffer containing 20 mM imidazole and spun down at 300 x g, to remove non-specific 
proteins. Proteins with a 6 x His tag were then eluted with 100 μL of Lysis Buffer containing 
50mM imidazole.  The eluted proteins were stored at -20 °C before separation with SDS-PAGE 




IX. Surface biotinylation 
Transiently transfected HEK293 cells in 6-well plates were washed with ice-cold PBS and then 
treated with 1mg/mL EZ-Link Sulfo-NHS-SS-Biotin (Thermo Fisher, Waltham, MA) in PBS for 
2 hours at 4 °C. The reaction was stopped by washing with PBS containing 100mM Tris (pH = 
7.5) for 15 minutes, and then the cells were lysed and harvested in Lysis Buffer (150mM NaCl, 
1mM EDTA, 0.1% SDS, 1% Triton X-100, 10mM Tris-HCl, pH=7.5) with Complete Protease 
Inhibitor Cocktail for 10 minutes. Lysates were centrifuged at 10,000 x g for 5 minutes and the 
resulting supernatants were added to Streptavidin-coupled Dynabeads (Thermo Fisher) and 
rotated end-over-end for 2 hours at room temperature. The beads were then centrifuged at 850 x g 
for 2 minutes and after two washes for 5 minutes each with Lysis Buffer, cell surface proteins 
were recovered by an incubation with Elution Buffer (2X Laemmli buffer containing 10% β-
mercaptoethanol diluted with an equal volume of Lysis Buffer containing 2X Protease Inhibitors) 
for 30 minutes at room temperature. After heating at 50°C for 10 minutes, cell membrane proteins 
were separated using SDS-PAGE followed by immunoblotting. 
 
X. Western blot analysis 
SDS-PAGE was performed with a mini-protean Tetra system from Bio-Rad.  Samples were 
mixed with 5X Laemmli-buffer (300mM Tris-Cl pH 6.8, 10% SDS, 50% glycerol, 0.05% 
bromophenol blue and 12.5%β-mercaptoethanol), heated to 50°C for 10 minutes, and then 
separated on 4%-20% gradient SDS gels (Expedeon, San Diego, CA) for 2 hours.  After SDS-
PAGE, separated proteins were transferred to PVDF membranes using the Trans-Blot Turbo 
Transfer system from Bio-Rad.  The membranes were then blocked with 5% non-fat milk in PBS 
for 1 hour at room temperature and incubated with the respective primary antibodies in 1% BSA 
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in PBS-Tween overnight at 4°C.  After 3 washes with PBS-Tween, HRP-conjugated secondary 
antibodies were added to the membrane for 1 hour at room temperature.  Protein bands were then 
visualized using the SuperSignal West Pico Chemiluminescent Substrate (ThermoFisher). 
 
XI. Cell-based uptake assay 
Cells plated in 24-well plates were carefully washed 3 times with prewarmed uptake buffer (for 
recipes of uptake buffers for different cell lines, see Table 2-2) and then incubated with 200 μL of 
uptake buffer containing substrate for the indicated time periods at 37°C. Uptake was stopped by 
removing the substrate solution and washing the cells with ice-cold uptake buffer 4 times. To 
quantitate uptake by the transporter, the cells were then solubilized with 300μL of 1% Triton X-
100 in PBS per well and 200μL were used for liquid scintillation counting. From the remaining 









CHO Flp-in cells 
CHO A-Cl KRH1 KRH2 
NaCl/Choline Chloride* 142mM 116.4mM - 118mM 125mM 
KCl 5mM 5.3mM 100mM 4.75mM 4.8mM 
KH2PO4 1mM - - - 1.2mM 
NaH2PO4 - 1mM - 1.2mM - 
NaHCO3 - - - 25mM - 
MgSO4 1.2mM 0.8mM - 1.2mM 1.2mM 
CaCl2 1.5mM - - 2.5mM 1.3mM 
Glucose 5mM 5.5mM - 11.12mM 5.6mM 
HEPES 12.5mM 20mM 25mM - - 
EGTA - - 2.5mM - - 
IBMX - - 20μM - - 
      
Tris buffer was used to adjust pH to 7.4 for all buffer. 
   





XII. Photoaffinity labeling 
Wild-type or OATP1B3 expressing CHO Flp-In cells were plated in 10 cm dishes at 1 million 
cells per dish and incubated for three days with complete culture medium listed above.  Dishes 
were then washed with 5 mL of A-Cl buffer (Table 2-2) twice to remove medium.  Five mL of A-
Cl buffer containing 8-fluorescein-cAMP (8-FcA) in the presence or absence of 100 μM losartan 
was added into the dishes, and immediately exposed under UV light (302 nm wavelength, UVP) 
for the indicated length of time (Figure 5-3) while control dishes without UV activation were kept 
in the dark.  To stop the reaction, cells were washed with 5 mL ice-cold A-Cl buffer three times.  
Membrane enriched fractions were isolated according to the protocol mentioned above, and 
analyzed by SDS-PAGE and western blot. 
 
XIII. Calculations and statistics 
All calculations were performed using Prism 6 (GraphPad Software Inc., San Diego, CA). Kinetic 
parameters were determined within the initial linear period of uptake after correction for protein 
and subtraction of uptake by the control cell line. Statistical analysis was performed with 





Organic Anion Transporting Polypeptide 1B3 can form homo- 
and hetero-oligomers 
Published: Plos one. June 23, 2017. 
I. Introduction 
Organic anion transporting polypeptide (OATP) 1B3 is a multispecific drug uptake transporter 
belonging to the SLCO superfamily (Hagenbuch and Stieger, 2013). Under normal physiological 
conditions OATP1B3 and the closely related OATP1B1 are selectively expressed at the 
sinusoidal membrane of human hepatocytes (Obaidat et al., 2012).  The two drug transporters are 
responsible for the uptake of numerous endogenous compounds, such as bile acids and hormones, 
and many xenobiotics including various drugs, into hepatocytes (Roth et al., 2012).  In addition, 
conjugated bile acids, including taurocholate or glycocholate, are transported into human 
hepatocytes via Na+/Taurocholate Cotransporting Polypeptide (NTCP) (Claro da Silva et al., 
2013) which has recently also been identified as the receptor for human hepatitis B and D virus 
(Yan et al., 2012).  
Drug uptake transporters contribute to drug metabolism like the cytochrome P450 drug-
metabolizing enzymes, and both can be modulated at different levels (Svoboda et al., 2011; 
Stieger and Hagenbuch, 2014).  The most direct way is to modulate OATP-mediated drug uptake 
with compounds that either inhibit or stimulate the transporter. Several studies have demonstrated 
that inhibition of OATP1B1 and/or OATP1B3 can lead to drug-drug-interactions (Konig et al., 
2013). For example, the rifampicin - bosentan interaction that was observed in healthy subjects 
(van Giersbergen et al., 2007) or the interaction between bosentan and sildenafil (Burgess et al., 
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2008) could both be explained by direct inhibition of OATP1B1- and OATP1B3-mediated 
bosentan uptake by rifampicin and sildenafil (Treiber et al., 2007). Besides inhibition, direct 
stimulation of OATP-mediated uptake has also been reported. OATP1B3-mediated uptake of 
estradiol-17β-glucuronide (E17βG) can be stimulated by clotrimazole (Gui et al., 2008) or a 
substituted quercetin (Zhang et al., 2013), OATP1B3-mediated uptake of estrone-3-sulfate (E3S) 
is stimulated by the green tea catechin epigallocatechin gallate (Roth et al., 2011), and 
OATP1B1- or OATP1B3-mediated uptake of pravastatin is stimulated by NSAIDS like 
diclofenac or ibuprofen (Kindla et al., 2011).  Importantly, these stimulatory effects increased the 
affinities of the substrates to the OATPs, indicating allosteric modulation.  Besides direct 
interactions with the transport protein, the function of OATPs can also be regulated at the 
transcriptional, translational, or even post-translational level (Powell et al., 2014; Stieger and 
Hagenbuch, 2014; Mayati et al., 2015). Furthermore, there is the potential for protein-protein 
interactions that could influence transporter function, similar as has been shown for drug-
metabolizing enzymes (Kandel and Lampe, 2014).  It has been demonstrated that some rat 
transporters expressed in hepatocytes, including NTCP (Bijsmans et al., 2012), and OCT1 can 
form homo-oligomers (Keller et al., 2008). In addition, a recent study showed that human 
OATP1B1 may form and function as oligomers (Ni et al., 2017). However, no such studies have 
been reported so far for human OATP1B3. Therefore, the goal of the present study was to 
investigate whether human OATP1B3 could form homo- or hetero-oligomers and how such 





2.1 Generation and characterization of different tagged OATP1B3 
Previous results from our lab showed that two bands were detected when OATP1B3 transiently 
expressed in HEK293 cells was analyzed on western blots; one at around 120kDa (normal size of 
OATP1B3) and another one at around 250kDa (Gui and Hagenbuch, 2008).  When the samples 
were treated with DTSSP, a crosslinker that contains a cleavable disulfide bond, the major band 
for OATP1B3 appeared around 250kDA and was reduced to about 120kDa in the presence of β-
mercaptoethanol (Figure 3-1). These results suggested that OATP1B3 could form dimers, either 
with itself or with other proteins.   
 
2Figure 3-1: Western blot of His-tagged OATP1B3. 
HEK293 cells transfected with empty vector (EV) or His-tagged OATP1B3 were treated with or 
without DTSSP. Whole cell lysates were separated on a 7.5% gel in the presence or absence of β-
mercaptoethanol (βME) and after transfer to a PVDF membrane His-tagged OATP1B3 was 
detected with an anti-His antibody.  
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We first wanted to test the hypothesis that OATP1B3 could form homodimers and performed co-
immunoprecipitation experiments using OATP1B3 constructs with different C-terminal tags.  In 
addition to the already published OATP1B3-His (Gui and Hagenbuch, 2008) we also constructed 
OATP1B3-HA and OATP1B3-FLAG and characterized these constructs.  Uptake of two model 
substrates, estradiol-17β-glucuronide (E17βG) and estrone-3-sulfate (E3S) was compared to 
OATP1B3-His which has the same function as wild type OATP1B3 (Gui and Hagenbuch, 2008). 
As can be seen in Figure 3-2A all three constructs mediated uptake of both model substrates to 
the same extent, suggesting that the newly constructed HA- and FLAG-tagged OATP1B3 have 
the same function as wild-type and His-tagged OATP1B3.  In order to test whether the 
commercial antibodies against the different tags would work for immunofluorescence and for the 
Proximity Ligations Assay (PLA) we first tested them using transiently transfected HEK293 
cells. Under normal conditions, the C-terminal end of OATP1B3 is on the cytoplasmic side (Abe 
et al., 2001) and an antibody reacting with the C-terminal end only stains cells if they have been 
permeabilized, e.g. with 1% Triton X-100. However, adding a tag of 6 to 9 amino acids with 
additional charges might change the topology of OATP1B3 at least at the C-terminal end. 
Therefore, we transiently transfected HEK293 cells with the three differently tagged OATP1B3 
and after 48 hours incubated the fixed HEK293 cells in the absence and presence of 1% Triton X-
100 before adding the respective antibodies. The results shown in Figure 3-2B demonstrate that 
the anti-His and anti-FLAG antibodies indeed only reacted with the transfected OATP1B3 after 
permeabilization with Triton X-100. However, the anti-HA antibody also resulted in positive 
staining in the absence of Triton X-100, suggesting that the C-terminal end of OATP1B3-HA is 
located at the extracellular side of the plasma membrane. None of the three antibodies used 
reacted with empty vector transfected HEK293 cells in the absence or presence of Triton X-100 




3Figure 3-2: Characterization of differently tagged OATP1B3 proteins. 
(A) Uptake of 10 µM estrone-3-sulfate (E3S) or 1 µM estradiol-17-β-glucuronide (E17βG) was 
measured at 37℃ with HEK293 cells transiently transfected with empty vector or OATP1B3 with 
a His-, HA- or FLAG-tag for 1 minute.  Values are means ± SD of three independent experiments 
each performed with triplicate measurements.  (B) HEK293 cells transiently transfected with 
OATP1B3 with a His-, HA- or FLAG-tag were fixed in the absence or presence of 1% TX-100.  
The different OATP1B3s were detected using the respective antibodies (shown in green) and 






4Figure 3-3:  Immunofluorescence control of the three antibodies used to detect His-, HA- 
and FLAG-tagged OATP1B3. 
HEK293 cells transiently transfected with empty vector were fixed in the absence or presence of 
1% TX-100.  The cells were then incubated with either anti-His, anti-HA or anti-FLAG 
antibodies followed by the respective secondary antibodies that should result in a green signal. 




2.2 Homo-oligomerization of OATP1B3 
To investigate whether OATP1B3 would be able to interact with itself, we transfected HEK293 
cells with equal amounts of His- and FLAG-tagged OATP1B3 and 48 hours later we 
immunoprecipitated the respective OATP1B3 either with an anti-His or an anti-FLAG antibody. 
As can be seen in Figure 3-4A, immunoprecipitation with the anti-His antibody followed by 
western blotting with an anti-His antibody results in the detection of the His-tagged OATP1B3. 
Immunoprecipitation with the anti-FLAG antibody followed by western blotting with the anti-His 
antibody also allowed detection of His-tagged, and therefore co-immunoprecipitated OATP1B3. 
The obtained signals are much stronger after treatment with the chemical crosslinker DTSSP 
(Figure 3-4A, right hand side).  Because the proteins were separated in the presence of β-
mercaptoethanol which cleaves DTSSP, the most of the immunoprecipitated proteins are seen at 
the molecular weight of the monomer. When the experiments were repeated with HA- and 
FLAG-tagged OATP1B3 and the western blot was probed with an HA-antibody a similar result 
was obtained (Figure 3-4B); immunoprecipitation with the HA-antibody also co-precipitated the 
FLAG-tagged OATP1B3. Thus, these results demonstrated that OATP1B3 can form homo-






5Figure 3-4: Immunoprecipitation of differently tagged OATP1B3 proteins.   
Membrane fractions isolated from HEK293 cells transiently transfected with OATP1B3-His and 
OATP1B3-FLAG (A) or OATP1B3-HA and OATP1B3-FLAG (B) and treated with or without 
DTSSP were solubilized. Immunoprecipitation was performed with Anti-His or Anti-FLAG 
antibodies (A), or Anti-HA or Anti-FLAG antibodies (B).  The eluted proteins were detected with 




To confirm the co-immunoprecipitation results with an additional experimental approach and to 
demonstrate that OATP1B3 interacts with itself in the plasma membrane we used the Duolink 
PLA.  In this assay the interaction or close proximity (<40 nm) of two proteins, here OATP1B3-
His and OATP1B3-FLAG or OATP1B3-FLAG with another His-tagged transporter (see below) 
is detected by using the respective anti-His and anti-FLAG antibodies that were raised in different 
species (rabbit anti-His and mouse anti-FLAG). After incubation with species specific secondary 
antibodies that have a short DNA sequence attached, the samples are incubated with linker DNA 
and a ligase to form DNA circles. Subsequently these circles are amplified in the presence of 
fluorescent nucleotides and the signals are detected using fluorescence microscopy. In Figure 3-5, 
a rabbit anti-His antibody and a mouse anti-FLAG antibody were used to perform PLA.  
Transfection of neither His- nor FLAG-tagged OATP1B3 alone resulted in any signals, 
demonstrating that there was no cross-reaction between the mouse and the rabbit PLA probe.  
However, when OATP1B3-His and OATP1B3-FLAG were co-transfected, clear signals at the 
plasma membrane could be detected, which confirmed the immunoprecipitation results and 
further demonstrated that OATP1B3 can form homodimers or oligomers when expressed in 




6Figure 3-5: DuoLink Proximity Ligation Assay (PLA) of OATP1B3-His and OATP1B3-
FLAG.   
HEK293 cells were transiently transfected with empty vector, OATP1B3-His, OATP1B3-FLAG 
or both OATP1B3-His and OATP1B3-FLAG.  After fixation, Duolink PLA was performed on all 
cells using a rabbit anti-His antibody in combination with a mouse anti-FLAG antibody.  Co-




2.3 Functional influence of OATP1B3 oligomerization 
Since there was abundant interaction of OATP1B3 at the plasma membrane, we further 
investigated whether oligomerization would affect transport activity.  We used a non-transporting 
mutant of OATP1B3, where the lysine at position 41 was replace by a cysteine, OATP1B3-
K41C-His. To ascertain that the mutant OATP1B3 is still capable of forming oligomers we 
repeated the co-immunoprecipitation experiment and co-transfected the His-tagged mutant with 
wild-type OATP1B3-FLAG. The results in Figure 3-6 demonstrate that in particular after 
crosslinking with DTSSP, immunoprecipitation with the His-tagged mutant OATP1B3-K41C 
will co-precipitate wild-type FLAG-tagged OATP1B3. We then measured uptake of the two 
model substrates E3S and E17βG after co-transfection and compared the results with transport 
obtained with single transfections of either wild-type OATP1B3-FLAG or the non-functional 
mutant OATP1B3-K41C-His (Figure 3-6B). If OATP1B3 oligomers would only work as a 
functional unit, and thus require two or more functionally active monomers, then the introduction 
of the mutant OATP1B3-K41C should abolish the whole unit and there should be less uptake, if 
any. However, uptake into HEK293 cells that were transfected with 500ng of OATP1B3-FLAG 
plus 500ng of OATP1B3-K41C-His (co-transfection) was 25-35% higher than uptake into 
HEK293 cells transfected with 500ng of OATP1B1-FLAG plus 500ng of empty vector 
(OATP1B3-FLAG). Uptake into HEK293 cells transfected with 500ng of OATP1B3-K41C-His 
plus 500ng of empty vector (OATP1B3-K41C) was as expected very low. This result indicates 
that each OATP1B3 in the dimer or multimer can transport on its own. However, why was 
transport higher after co-transfection as compared to single transfection? We transfected HEK293 
cells with increasing amounts of OATP1B3 plasmid (up to 1,000 ng per well) and measured 
uptake. The results demonstrated that uptake after transfection with 1,000 ng was more than twice 
the uptake after transfection with 500ng of plasmid (Figure 3-7) suggesting that the amount of 
OATP1B3 at the plasma membrane was affected. Therefore, we used surface biotinylation to 
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determine the relative amounts of wild-type OATP1B3-FLAG and mutant OATP1B3-K41C-His 
at the plasma membrane after individual or co-transfection. The results shown in Figure 3-6C 
show that after co-transfection indeed more OATP1B3 protein was detectable at the plasma 
membrane, explaining the increased uptake. After correcting for this increased amount of protein 
expressed at the membrane (OATP1B3 at the membrane after single transfection was set to 100% 
after correction with Na+/K+ ATPase) uptake was the same for the single wild-type OATP1B3-
FLAG only or the co-transfection with the nonfunctional mutant OATP1B3-K41C-His (co-
transfection) (Figure 3-6D).  OATP1B3-FLAG plus 500ng of pcDNA5/FRT (WT), or with 500ng 
of OATP1B3-FLAG plus 500ng of OATP1B3-K41C-His (Co-Transfection). Forty-eight hours 
later uptake of 10µM E3S or 1µM E17βG was performed at 37°C for 1 min. (C) Surface 
biotinylated proteins were isolated from HEK293 cells transiently transfected as in (B). Western 
blot was performed with Anti-His (Mutant-His) or Anti-FLAG (WT-FLAG). Na+/K+ ATPase was 
used as loading control. (D) Uptake shown in (B) was normalized by the surface expressed 
mutant-His or WT-FLAG protein determined in (C) after subtracting of empty-vector control 
uptake. 
To investigate whether dimerization/oligomerization with the mutant OATP1B3 would affect 
transport kinetics, we performed concentration dependent uptake measurements with E17βG in 
the absence and presence of clotrimazole, a known OATP1B3 stimulator. As can be seen in Table 
3-1, there was no difference in the Km values for the monomer as compared to the 
dimer/oligomer. We would have expected that the Vmax value would be decreased by about 50 % 
because only 50% of the functional OATP1B3 was transfected. However, the decrease was only 
40% which might be due to the small and statistically not significant signal seen with the mutant 
alone (Figure 3-6B). In addition, similar to our previous report (Gui et al., 2008), the addition of 
clotrimazole increased the affinity for both the monomer as well as for the dimer/oligomer, 
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suggesting that the allosteric stimulation is not affected by the dimer/oligomer formation and that 





7Figure 3-6: Effect of co-transfection of a-non-functional OATP1B3 mutant on function and 
oligomerization.  
(A) Membrane fractions isolated from HEK293 cells transiently transfected with OATP1B3-
FLAG and OATP1B3-K41C-His and treated with or without DTSSP were solubilized. 
Immunoprecipitation was performed with Anti-His or Anti-FLAG antibodies and the eluted 
proteins were detected with Anti-His antibody. (B) HEK293 cells were transiently transfected 





8Figure 3-7:  Effect of co-transfection of different ratios of empty vector and OATP1B3-
FLAG. 
Uptake of 1 µM estradiol-17β-glucuronide (E17βG) was measured at 37°C with HEK293 cells 
transiently transfected with a total amount of 1000 ng of cDNA for 1 minute.  Mean ± SD of the 
percentage of OATP1B3-FLAG cDNA is indicated on the x-axis. 
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4Table 3-1: Effect of clotrimazole on kinetics of wild-type OATP1B3 in the absence and 
presence of the non-transporting OATP1B3-K41C.  
Transporter E17βG   E17βG + 30µM clotrimazole 
 Km (µM) Vmax (pmol/mg 
protein x min-1) 
Km (µM) Vmax (pmol/mg 
protein x min-1) 
WT-OATP1B3 7.1 ± 0.9 78 ± 3.3 3.3 ± 1.0 107 ± 8.3 
WT-OATP1B3 + 
OATP1B3-K41C 
5.5 ± 1.7 48 ± 4.5 3.6 ± 1.3 68 ± 6.5 
HEK293 cells were transfected with 500ng of His-tagged OATP1B3 (WT-OATP1B3) or 250ng 
of His-tagged OATP1B3 plus 250ng of His-tagged OATP1B3-K41C. Kinetic parameters were 
determined based on the 30 secs uptake of 1, 5, 10, 20, 30 and 50μM E17βG in the absence or 
presence of 30μM clotrimazole.  
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2.4 Hetero-oligomerization between OATP1B3 and other transporters 
Given that OATP1B3 can form homodimers/oligomers, we asked the question whether 
OATP1B3 would also interact with other transporters also expressed in the basolateral membrane 
of human hepatocytes, such as OATP1B1 an NTCP. We performed Duolink PLA experiments 
using HEK293 cells that were transiently transfected with OATP1B3-FLAG and His-tagged 
OATP1B1 or NTCP. As a negative control we used His-tagged ASBT which is not expressed in 
human hepatocytes. As shown in Figure 3-8 on the left side, all the His-tagged proteins were 
expressed and could be detected by immunofluorescence (IF) with an anti-His antibody. Figure 3-
8 also demonstrates (right side) that the co-expression of OATP1B3 with either OATP1B1 or 
with NTCP resulted in good PLA signals at the plasma membrane, suggesting the formation of 
hetero-oligomers of the two respective proteins.  Importantly, the fact that co-expression of 
OATP1B3 with ASBT did not result in any signals demonstrates that the proximity of the 






9Figure 3-8: DuoLink PLA of OATP1B3-FLAG and other His-tagged transporters 
expressed in HEK293 cells. 
HEK293 cells were transiently transfected with His-tagged OATP1B1, ASBT or NTCP only or 
with these His-tagged transporters plus OATP1B3-FLAG.  After 48 hours, cells were fixed and 
processed for immunofluorescence (IF) (signals in green) or Duolink PLA (signals in red). 
Nuclear staining is shown in blue.  
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To further confirm that OATP1B3 and NTCP also interact in human liver and not only in 
transfected HEK293 cells, we performed PLA experiments using frozen human liver tissues.  
Figure 3-9 shows that compared to the OATP1B3 negative control, positive PLA signals were 
obtained for the OATP1B3 positive control as well as for the OATP1B3-NTCP interaction, 
confirming that OATP1B3 and NTCP also interact in human liver. 
 
10Figure 3-9: Co-localization of OATP1B3 with NTCP in human liver.   
Frozen human liver sections were used to perform Duolink PLA. For the OATP1B3 negative 
control an anti-rabbit minus and an anti-mouse plus PLA antibody were used; for the OATP1B3 
positive control, an anti-rabbit minus was combined with an anti-rabbit plus PLA antibody. To 
co-localize OATP1B3 with NTCP, a goat anti-NTCP antibody was combined with the rabbit anti-
OATP1B3 antibody. Co-localization is shown in red, nuclei are stained with DAPI and are shown 




In this study, we demonstrated that the important hepatocellular drug transporter OATP1B3 can 
form homo-dimers or -oligomers. In these dimers/oligomers an individual OATP1B3 seems to be 
the functional unit because co-transfections with a nonfunctional OATP1B3-K41C mutant did not 
affect uptake of E3S and E17βG. Furthermore, we also established that OATP1B3 can form 
hetero-dimers/oligomers in HEK293 cells with other hepatocellular transporters like OATP1B1 
and NTCP, and we verified the interaction with NTCP using frozen human liver sections.  
Several lines of evidence support our findings. Co-immunoprecipitation experiments confirmed a 
physical interaction between OATP1B3-His and OATP1B3-FLAG (Figure 3-4), while the 
Proximity Ligation Assay verified a close association of the two differently tagged OATP1B3 
proteins (Figure 3-5).  Besides that, our data also show that the C-terminal end of OATP1B3 is 
not involved in dimerization/oligomerization because both His-tagged OATP1B3 with the C-
terminal end on the cytoplasmic side of the membrane as well as HA-tagged OATP1B3 with the 
C-terminal end on the extracellular side of the membrane (Figure 3-2B) were able to co-
immunoprecipitate FLAG-tagged OATP1B3 (Figure 3-4B). At the functional level, our results 
show that a non-functional unit (OATP1B3-K41C) in the homo-dimer/oligomer does not affect 
normal substrate transport of OATP1B3, nor does it affect the modulation of transport by 
clotrimazole. These results suggest that each unit within the dimer/oligomer works as an 
independent functional unit, which is similar to previous findings regarding NTCP (Bijsmans et 
al., 2012). However, our co-transfection studies with the non-functional mutant did not yield any 
structural information with respect to potentially involved amino acid residues or transmembrane 
domains. A recent report suggested that GXXXG motifs present in OATP1B1 are involved in the 
oligomerization of OATP1B1 (Ni et al., 2017). The three GXXXG motifs in OATP1B1 are 
completely conserved in OATP1B3 and therefore, it is possible that G393 in the third GXXXG 
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motif indeed is involved in the homo-oligomerization. Given that there are also three GXXXG 
motifs in NTCP, it is possible that these motifs play also a role in hetero-oligomerization or that 
they are important in intramolecular interactions and stabilize proper folding (Teese and 
Langosch, 2015). To evaluate these possibilities future experiments are required, including e.g. 
mutational analysis where the glycine residues are replaced by other amino acid residues besides 
alanine, and determining the effect these mutations have on plasma membrane localization of the 
proteins.  
Using the proximity ligation assay in transiently transfected HEK293 cells we also demonstrated 
that OATP1B3 interacts with OATP1B1 and with NTCP, two additional transporters expressed at 
the basolateral membrane of human hepatocytes. Furthermore, we confirmed the interaction 
between OATP1B3 and NTCP on frozen human liver sections. Assuming that these interactions 
between the two different transport proteins are direct protein-protein interactions we can 
speculate that the two proteins might affect each other’s function. This could have consequences 
for potential drug-drug interactions studies (see below). In contrast, if the two proteins do not 
directly interact and are just expressed in the same micro-domains, then OATP1B3 and NTCP 
might be regulated in a similar manner, at least at the post-translational level. Again, additional 
experiments are required to characterize these options in detail. The functional consequences of 
these interactions will have to be evaluated in future studies. The proximity ligation assay only 
demonstrates that two proteins are closer than 40nm but does not prove a direct physical 
interaction between the two proteins. Thus, additional experiments will be required to investigate 
whether the identified interaction partners, OATP1B1 and NTCP, are directly interacting with 
OATP1B3 or whether they reside together in the same membrane micro-domains. So far, we only 
demonstrated direct interaction between His-tagged OATP1B3 and FLAG-tagged OATP1B3, 
proving direct homo-oligomerization, while similar experiments with OATP1B1 and NTCP are 
still missing.  
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Previous western blot data suggested such homo- or hetero-dimerization/oligomerization for 
OATP1B3 (Gui and Hagenbuch, 2008), for OATP1B1 (Gui and Hagenbuch, 2009), as well as for 
other solute carriers including ASBT (Kramer et al., 2001a), Na+-K+-2Cl- cotransporter (NKCC1) 
(Moore-Hoon and Turner, 2000), SLC10A5 (Fernandes et al., 2007), and SLC10A7 (Godoy et al., 
2007). Furthermore, it was demonstrated that NTCP can homo- and heterodimerize with other 
members of the SLC10A family (Bijsmans et al., 2012). Thus, it is very likely that many solute 
carriers work as functional dimers/oligomers and could potentially be located in the same 
membrane micro-domains. 
The fact that OATP1B3 can hetero-oligomerize with other transporters suggests that these 
transporters potentially influence each other’s function and even might be regulated in a similar 
manner at the protein level.  
Most OATPs show increased function at an acidic pH value (Leuthold et al., 2009; Martinez-
Becerra et al., 2011). While this seems to be an advantage for an intestinal transporter one could 
argue that it should not affect a transporter expressed at the basolateral membrane of hepatocytes. 
However, co-localization in membrane micro-domains or direct interactions with a Na+/H+-
exchanger could lead to an acidic microenvironment which could increase OATP function. 
Furthermore, if indeed the microenvironment generated around these transporter micro-domains 
influences the physiological or pharmacological function of the involved drug transporters, drug-
drug interaction studies should be performed with cell lines that express multiple transporters 
rather than just a single transporter. Recent findings with members of the drug metabolizing 
enzymes of the cytochrome P450 family suggest that in vitro systems with more than a single 
transporter are not only more physiological but might indeed demonstrate that that the different 
transporters affect each other’s function. The activity of CYP2C9 was modified by co-expression 
with different amounts of CYP3A4 (Ramsden et al., 2014). In analogy, OATP1B3 activity could 
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be modulated by any of the interacting transporters and vice versa and as a consequence, the 
functional importance of OATP1B3 interaction with other transporters will have to be evaluated. 
In summary, we have shown that the multi-specific liver transporter OATP1B3 can form homo-
oligomers and can interact with other transporters in liver including OATP1B1 and NTCP. We 
also demonstrated that the homo-oligomers work as two or more individual functional subunits. 
Our findings are important because they suggest the existence of transporter micro-domains 
containing OATPs, and as a consequence functional transporter studies might have to be modified 









Hetero-oligomerization affects Organic Anion Transporting 
Polypeptide 1B3 (OATP1B3) expression and function 
I. Introduction 
Uptake of endo- and xenobiotics into human hepatocytes is mediated by several drug uptake 
transporters that are expressed at the sinusoidal membrane, including organic anion transporting 
polypeptide 1B1 (OATP1B1) and OATP1B3 (Hagenbuch and Stieger, 2013), the organic cation 
transporter 1 (OCT1) (Koepsell, 2013) as well as the Na+/taurocholate cotransporting polypeptide 
(NTCP) (Claro da Silva et al., 2013). OATP1B1 and OATP1B3 transport mainly organic anions 
but also neutral compounds, and have partial overlapping substrate selectivities (Konig, 2011; 
Hagenbuch and Stieger, 2013). Among the transported substrates are endobiotics like bile acids, 
bilirubin, steroid hormone metabolites, thyroid hormones, glutathione, inflammatory mediators 
and coproporphyrins (Stieger and Hagenbuch, 2014; Bednarczyk and Boiselle, 2015), as well as 
numerous drugs (Roth et al., 2012). 
Several model substrates, including estradiol-17β-glucuronide, bromosulfophthalein and 
cholecystokinin-8 (CCK-8) have been used to characterize OATP1B3 function (Hagenbuch and 
Stieger, 2013), but among them, only CCK-8 is OATP1B3 selective (Ismair et al., 2001). OCT1 
is also a multispecific transporter and mainly mediates the uptake of organic cations and some 
neutral compounds, including the neurotransmitters serotonin, dopamine and norepinephrine, as 
well as acetylcholine (Koepsell et al., 2007; Boxberger et al., 2014), and numerous drugs 
including metformin, protease inhibitors and anti-cancer agents (Nies et al., 2011; Koepsell, 
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2013). Besides metformin, the model substrates tetraethylammonium (TEA) and 1-methyl-4-
phenylpyridinium (MPP+) are often used to characterize OCT1 transport (Gorboulev et al., 1997; 
Zhang et al., 1997) and given that these are cationic, they are not substrates of OATPs. NTCP is 
important for the uptake of bile acids into hepatocytes to maintain their enterohepatic circulation 
but can also transport several drugs, including statins (Claro da Silva et al., 2013). It has also been 
identified as the receptor for the hepatitis virus B and D (Yan et al., 2014).  
We recently demonstrated that besides homo-oligomers, OATP1B3 can form hetero-oligomers 
with the two liver transporters OATP1B1 and NTCP (Zhang et al., 2017).  In addition, a 
DUALmembrane screening (Stagljar et al., 1998), a modified yeast two-hybrid screening, 
identified OCT1 as a likely interaction partner. However, the functional consequences of these 
hetero-oligomers remain unknown.  Because the FDA guidelines for the study of transporter-
mediated drug-drug interactions (DDIs) include OATP1B3, OATP1B1, NTCP and OCT1 as 
potential targets for DDIs, it is important to understand the influence of the hetero-
oligomerization of OATP1B3 with these three transporters. Therefore, in the present study we 
tested whether OATP1B3 and OCT1 indeed interact with each other, and we characterized the 






2.1 OATP1B3 and OCT1 interact in human hepatocytes. 
In order to investigate whether OATP1B3 would interact with other human liver proteins, 
Dualsystems AG (Schlieren, Switzerland) performed a DUALmembrane screening with full-
length OATP1B3 as the bait. Screening a human adult liver cDNA library resulted in the isolation 
of 51 cDNAs that were further analyzed and classified. Nineteen of these cDNAs were very likely 
unspecific interactors because they were found in 20-50% of the screenings, independent of the 
bait. Among the other 32 that were considered to be screen-specific interactors organic cation 
transporter 1 (OCT1), encoded by SLC22A1, was found three times. Given that OCT1, like 
OATP1B3, is a drug uptake transporter expressed at the basolateral membrane of human 
hepatocytes, we further investigated this potential interaction by performing co-
immunoprecipitation experiments. As can be seen in Figure 4-1A, OCT1 could be detected with 
an OCT1-specific antibody on a western blot of proteins that were immunoprecipitated from 
solubilized human hepatocytes with an anti-OATP1B3 antibody. The signal at approximately 75 
kDa was stronger in the presence of the crosslinker DTSSP. To further confirm this OATP1B3-
OCT1 interaction in human liver, we performed proximity ligation assays on frozen sections of 
human livers. The proximity ligation assay detects interacting proteins that are less than 40nm 
apart (Soderberg et al., 2006) using two antibodies raised in different species. If these two 
proteins are less than 40nm apart, the assay will result in a red signal. We previously used this 
assay to demonstrate OATP1B3-NTCP interactions in frozen human liver slices (Zhang et al., 
2017). When we incubated frozen human liver sections only with the monoclonal antibody 
recognizing OCT1, no red signal was generated (Figure 4-1B; OCT1). However, when the 
monoclonal anti-OCT1 antibody was used together with the polyclonal anti-OATP1B3 antibody 
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(K28), interactions between the two transporters were evident by the red signals (Figure 4-1B; 




11Figure 4-1: OATP1B3 and OCT1 interact in human hepatocytes.  
Interaction of OATP1B3 with OCT1 is demonstrated by (A) co-immunoprecipitation and (B) 
with a proximity ligation assay. (A) Solubilized proteins from freshly isolated and plated human 
hepatocytes were incubated with an anti-OATP1B3 antibody in the presence or absence of the 
crosslinking agent DTSSP. After precipitating the anti-OATP1B3 antibodies with protein A 
beads, the resulting supernatants (S) and pellets (P) were separated by SDS-PAGE and after 
transfer to a PVDF membrane incubated with an anti-OCT1 antibody. (B) Frozen human liver 
sections were incubated either with only an anti-OCT1 antibody or with a combination of anti-
OCT1 and anti-OATP1B3 antibodies. After incubation with the respective secondary antibodies 
and the ligation reaction mix, interactions were detected in red. The blue color represents DAPI 




2.2 OATP1B3 and OCT1 interact in HEK293 cells. 
To characterize the functional consequences of the OATP1B3-OCT1 interactions we wanted to 
use transiently transfected HEK293 cells. Therefore, we first tested whether these protein-protein 
interactions could also be demonstrated with the proximity ligation assay when both transporters 
were expressed in HEK293 cells. The results in Figure 4-2A show that OATP1B3 and OCT1 also 
interact when expressed in HEK293 cells. As a negative control we transfected OATP1B3 
together with ASBT, a transporter which is expressed in cholangiocytes and enterocytes. The lack 
of a signal (Figure 4-2B) demonstrates that the interaction of OATP1B3 with OCT1 in HEK293 
cells is not due to unspecific overexpression of any membrane protein but due to specific 






12Figure 4-2: OATP1B3 and OCT1 interact in transiently transfected HEK293 cells.  
Interaction of OATP1B3 with OCT1 is demonstrated using the proximity ligation assay. HEK293 
cells were transfected with (A) OATP1B3-His and OCT1 plasmids (1:1), or (B) OATP1B3-
FLAG and ASBT-His plasmids (1:1).  Twenty-four hours after transfection HEK293 cells were 
fixed and incubated with a combination of corresponding antibodies. After incubation with the 
respective secondary antibodies and the ligation reaction mix, interactions can be detected in red. 
The blue color represents DAPI staining of the nuclei.   
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2.3 Plasma membrane expression of OATP1B3 is affected by hetero-oligomerization in 
HEK293 cells. 
After the demonstration of interaction between OATP1B3 and OCT1 in HEK293 cells, we asked 
the question whether expression at the plasma membrane would be affected by co-expression of 
OATP1B3 with OCT1.  Because we recently demonstrated that OATP1B3 can also interact with 
OATP1B1 and NTCP (Zhang et al., 2017), we also looked at the effect of co-expression of 
OATP1B3 with these two transporters.  OATP1B3 was transfected in HEK293 cells either alone 
(co-transfected with empty vector) or together with OCT1, or OATP1B1, or NTCP, and 
membrane proteins were labeled and isolated using the biotin-streptavidin system.  Plasma 
membrane expression of OATP1B3, OCT1, OATP1B1, and NTCP was then quantified by SDS-
PAGE and western blot.  As can be seen in Figure 4-3A, no OATP1B3 was visible when only 
empty vector or OCT1 were transfected. When OATP1B3 was transfected together with empty 
vector more biotinylated OATP1B3 was detected and thus more OATP1B3 was expressed at the 
plasma membrane than when OATP1B3 was co-expressed with OCT1. After quantification and 
normalization for the Na+/K+ATPase signal, we calculated that co-expression of OCT1 reduced 
the OATP1B3 signal to about 20% (Figure 4-3B). In contrast, expression levels for OCT1 co-
transfected with OATP1B3 did not change significantly as compared to co-transfection with 
empty vector (Figure 4-3A, B). Interestingly, OATP1B3 protein expression was increased 
significantly when co-expressed with either OATP1B1 or NTCP (Figure 4-3C). Quantification 
and normalization with the Na+/K+ ATPase signal revealed an about 4.5fold and 2.5fold increase 
in plasma membrane expression when co-expressed with OATP1B1 and NTCP, respectively, 
while expression of OATP1B1 and NTCP was not affected (Figure 4-3D). Given that only 
transporters expressed at the surface of HEK293 cells can transport their substrates, these surface 




13Figure 4-3: Plasma membrane expression of OATP1B3 and interacting transporters when 
co-expressed in HEK293 cells.  
HEK293 cells were transfected with empty vector (EV), empty vector and OATP1B3-His (1:1), 
empty vector and OCT1 (1:1), or OATP1B3-His and OCT1 (1:1).  Since both OATP1B1 and 
NTCP contain a His tag inserted at the C-terminal end, the same transfection conditions were 
used but OATP1B3-His was replace by a OATP1B3-FLAG plasmid.  Twenty-four hours (for 
OCT1), or 48 hours (for OATP1B1 and NTCP) after transfection, surface biotinylation 
experiments were performed and membrane proteins were harvested and analyzed by western 
blot.  A and C: Membrane proteins were detected using the indicated antibodies, or a Na+/K+-
ATPase antibody as loading control.  B and D: Relative intensity of western blot bands were 
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quantified and compared based on three independent experiments; mean ± SD are shown for the 
co-transfections. 
 
2.4 Hetero-oligomerization in HEK293 cells affects OATP1B3-mediated CCK-8 
transport. 
To determine whether the interaction between OATP1B3 and OCT1 or OATP1B1 or NTCP also 
affects OATP1B3 transport function, we compared uptake of the OATP1B3 specific substrate 
CCK-8 into HEK293 cells transfected with OATP1B3 and empty vector, or OATP1B3 and the 
respective interacting transporters. Twenty-four hours (for co-transfection with OCT1), or 48 
hours (for co-transfection with OATP1B1 or NTCP) after transfection uptake of 1 µM 3H-CCK-8 
was measured for 1 minute at 37 °C. As can be seen in Figure 4-4A, uptake of CCK-8 was 
detected in OATP1B3 expressing HEK293 cells but was absent in cells transfected with empty 
vector, OCT1, OATP1B1 or NTCP. When OATP1B3 was co-expressed with OCT1 uptake was 
reduced to 50% (Figure 4-4A, top). However, when normalized for plasma membrane expressed 
OATP1B3 this 50% reduction of transport was actually a 2.7fold stimulation (Figure 4-4B, top). 
Thus, although the initial observation indicated decreased OATP1B3 transport, co-expression 
with OCT1 actually stimulated CCK-8 uptake. Interestingly, an opposite effect was observed with 
OATP1B1 or NTCP.  Before normalization, uptake of CCK-8 by OATP1B3 was not significantly 
affected by co-expression with both, OATP1B1 or NTCP (Figure 4-4A, middle and bottom). 
However, after normalization for membrane expressed OATP1B3, uptake of CCK-8 was reduced 
dramatically (Figure 4-4B, middle and bottom).  We next determined the initial linear portion of 
CCK-8 uptake for OATP1B3 expressed alone and co-expressed with the three different 
transporters to be able to characterize kinetics. Based on these experiments, we performed CCK-8 
uptake experiments with increasing CCK-8 concentrations (0.1 to 50 µM) at 1 minute. As shown 
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in Figure 4-5A (summarized in Table 4-1), 24 hours after transfection, saturable CCK-8 uptake 
with a Km value of 10.9 ± 1.9 µM and a Vmax value of 166 ± 10 pmoles/mg protein x min could be 
calculated for OATP1B3. When OCT1 was co-expressed and the values were normalized for 
plasma membrane expression of OATP1B3 the Km value did not change but the Vmax increased to 
253 ± 10 pmoles/mg x min.  Fourty-eight hours after transfection, the Km value remained the 
same when OATP1B3 expressed with or without OATP1B1 or NTCP, but the Vmax decreased 





14Figure 4-4: Functional consequences for OATP1B3 when co-expressed with OCT1, 
OATP1B1 or NTCP.  
Uptake experiments with 1µM 3H-CCK-8 were performed 24-hours (OCT1) or 48-hours 
(OATP1B1 and NTCP) after HEK293 cells were transiently transfected with an equivalent 
amount of cDNA with the indicated combination of plasmids or empty vector (EV).  Uptake was 
terminated after 1 minute and normalized by total protein concentration (A) or surface expressed 
protein (B).  The means ± SD of three experiments (n=3) are shown; an asterisk indicates a p < 





15Figure 4-5: Effects of co-expression of interacting transporters on the kinetics of OATP1B3-
mediated cholecystokinin-8 (CCK-8) uptake.  
Uptake of increasing concentrations of 3H-CCK-8 (0.1 - 50 µM) was measured at 37°C for 1 
minute in HEK293 cells transiently transfected with 500ng of empty vector, or 250ng of empty 
vector mixed with 250ng of OATP1B3 (OATP1B3/EV), or 250ng of OATP1B3 mixed with 
250ng of respective interacting transporters.  Uptake was normalized by total and plasma 
membrane expressed protein. After subtracting the values obtained with empty vector transfected 
cells, net OATP1B3-mediated uptake was fitted to the Michaelis–Menten equation to obtain Km 
and Vmax values. Means ± S.E. of 7 (A: for interaction with OCT1) or 3 (B: for interaction with 
either OATP1B1 or NTCP) individual experiments each performed with triplicate determinations 
are given. Circles and a solid line represent OATP1B3/EV transfected cells while squares and a 




5Table 4-1: Kinetic parameters for OATP1B3-mediated uptake of CCK-8 in single- or co-
transfected HEK293 cells. 
Transfection Condition Km (µM) Vmax (pmol/mg protein x min) 
OATP1B3/EV (24 hours) 10.9 ± 1.9 166 ± 10 
OATP1B3/OCT1 (24 hours) 9.8 ± 1.1 253 ± 10* 
OATP1B3/EV 16.9 ± 3.2 477 ± 36 
OATP1B3/OATP1B1 27.4 ± 3.6* 164 ± 10* 
OATP1B3/NTCP 29.2 ± 7.2* 224 ± 27* 




2.5 Hetero-oligomerization in HEK293 cells does not seem to affect the function of 
OCT1, OATP1B1 and NTCP. 
Finally, to investigate whether the function of the OATP1B3 partner proteins would be affected 
by the co-expression, we measured uptake of representative model substrates for OCT1 
(metformin), OATP1B1 (low concentration of estrone-3-sulfate) and NTCP (taurocholate) after 
co-transfecting HEK293 cells. The results in Figure 4-6 demonstrate that the function of neither 
of the three interacting transport proteins was affected by co-expression with OCT1. 
 
16Figure 4-6: Functional consequences for interacting transporters when co-expressed with 
OATP1B3.  
Five-minute uptake of 5µM 14C-metformin (for OCT1), 1 minute uptake of 0.1µM E3S (for 
OATP1B1) or 1µM TCA (for NTCP) were measured 24-hours (for OCT1), or 48-hours (for 
OATP1B1 and NTCP) after HEK293 cells were transiently transfected with an equivalent amount 
of cDNA with indicated combinations.  Substrate-mediated uptake was normalized by total and 
plasma membrane expressed protein concentrations. Means ± SD are given for three experiments 




In the present study we could demonstrate, using co-immunoprecipitation and proximity ligation 
assays, that OATP1B3 and OCT1 interact with each other in human hepatocytes as well as when 
expressed in HEK293 cells. Co-expression of OCT1 with OATP1B3 in HEK293 cells reduced 
OATP1B3 protein expression at the plasma membrane as compared to when OATP1B3 was 
expressed alone. In addition, we could show that these protein-protein interactions affected the 
function of OATP1B3 in a transporter-dependent manner. Furthermore, OATP1B3 expression at 
the plasma membrane was increased when co-expressed with OATP1B1 or NTCP. 
Under normal physiological conditions OATP1B3 is exclusively expressed at the basolateral 
membrane of human hepatocytes with highest expression levels around the central vein (König et 
al., 2000; Cui et al., 2003). A similar lobular expression was also reported for mouse OCT1 
(Chen et al., 2014).  Although we do not yet know the mechanisms by which the OCT1-
OATP1B3 protein-interaction results in down-regulated OATP1B3 protein, a similar protein-
protein interaction between the corresponding two proteins in mice, mouse OCT1 and mouse 
OATP1B2, respectively, could be responsible for the differential regulation in a mouse model of 
nonalcoholic steatohepatitis (NASH) due to a methionine- and choline-deficient diet. In these 
animals OATP1B2 is down-regulated (Clarke et al., 2014a) while OCT1 expression goes up as 
compared to healthy controls (Clarke et al., 2015).  Interestingly, OATP1B3 protein expression 
was much lower in NASH livers when compared to normal livers (Clarke et al., 2014b) but there 
is no information available yet on OCT1 expression under the same conditions in these mice. 
Nevertheless, our findings support the speculation that changes at the protein level of OCT1, 
either due to disease or due to polymorphisms, can affect the expression of OATP1B3 most likely 
through post-translational regulation. 
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Uptake of the OATP1B3-specific substrate CCK-8 increased when OATP1B3 was co-expressed 
with OCT1 (Figure 4-4B). This increased transport was due to an increased Vmax with a constant 
Km value (Figure 4-5 and Table 4-1). The Vmax can increase either due to increased transporter 
expression at the plasma membrane or due to an increased transporter turnover rate. Because we 
normalized the results for plasma membrane expression of OATP1B3, our data demonstrate that 
the turnover rate was increased when OATP1B3 was co-expressed with OCT1.  
Interestingly, a completely different effect was observed when OATP1B3 was co-expressed with 
OATP1B1 or NTCP.  Unlike OCT1, OATP1B1 and NTCP have an even distribution throughout 
the liver lobule, which could potentially explain the reversed effect on OATP1B3 compared to 
OCT1. 
We have demonstrated that co-expression of OATP1B3 with other transporters can affect its 
function. Thus, because in human hepatocytes both transporters can be expressed in the same 
hepatocyte, this co-expression likely affects the physiological function of OATP1B3 and/or its 
ability to clear drugs. When characterizing and predicting drug-drug interactions researchers 
normally use HEK293 or CHO cells that express a single transporter (Hirano et al., 2006; Noe et 
al., 2007; Gui et al., 2008). However, given that these drug transporters might be affected by co-
expressed transporters, these single expression systems do not really reflect the situation in 
human hepatocytes and results obtained in the single transfection systems could be misleading. 
Experiments with several drugs, e.g. statins or sartans should be conducted in the future in the co-
expression systems to confirm that the single transporter expression system is a good enough 
system or to demonstrate that multiple transporter expression systems should be used instead of 
or at least in combination with the single transporter systems. 
The presented results demonstrate that the expression of OATP1B3 at the protein level and in 
addition at the plasma membrane is affected by co-expression with OCT1, OATP1B1 or NTCP 
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(Figure 4-3). We have preliminary data suggesting that the expression levels obtained in our 
experiments are affected by the ratios of the transfected plasmids. Furthermore, the total protein 
expression levels of both proteins are two to four-fold higher than the respective levels in human 
hepatocytes. Thus, for an ideal simulation system, the respective protein levels will have to be 
adjusted to reflect average protein levels in human hepatocytes.  
Regulation of OATP1B3 and other OATPs has mainly been studied at the transcriptional level 
(reviewed in (Hagenbuch and Stieger, 2013)). Limited information is available for post-
translational regulation via protein kinase C activation (Guo and Klaassen, 2001; Kock et al., 
2010; Powell et al., 2014; Hong et al., 2015) and several mainly rodent OATPs have been 
reported to interact with adapter proteins of the PDZ family (summarized in (Stieger and 
Hagenbuch, 2014)). Similar interactions could occur with additional transporters in the 
basolateral membrane of human hepatocytes involving other OATPs, OCTs and NTCP. The fact 
that co-expressed transporters interact might suggest that they also could be co-regulated at the 
post-translational level. Thus, further experiments need to be conducted to investigate whether 
this indeed is the case.  
The interaction between carbonic anhydrase II and the epithelial sodium-proton exchanger NHE3 
results in increased activity of NHE3 (Krishnan et al., 2015). In the case of carbonic anhydrase 
and NHE3, functional active carbonic anhydrase is required. Thus, we will need to test in the 
future how the observed functional consequences are modified when transporters with 
inactivating or stimulating polymorphisms are co-expressed.  
Whether these effects are mediated through direct protein-protein interactions or via integration 
of the transporters into lipid raft domains as has been shown for rat NTCP (Molina et al., 2008), 
for rat OCTN2 (Czeredys et al., 2013), and for rat OAT3 (Srimaroeng et al., 2013) remains to be 
determine in future experiments.    
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In summary, we have shown that the hepatocellular drug transporters OATP1B3 and OCT1 
interact with each other and that this interaction can increase OATP1B3-mediated uptake of 
CCK-8, but reduce the plasma membrane expression level of OATP1B3.  The interaction 
between OATP1B3 and OATP1B1, or NTCP led to an opposite effect, decreasing the function of 
OATP1B3 but increasing its plasma membrane expression level.  These findings are important 
because they suggest that the clearance of endogenous compounds as well as of drugs can be 
affected by co-expressed proteins and thus that the characterization of these drug transporters in 
single transfected recombinant systems might well lead to over- or underestimation of the effects 
of drug-drug interactions. Therefore, we should consider test systems that co-express the involved 








Identification of binding sites and translocation pathway of 
OATP1B3 by photoaffinity labeling 
I. Introduction 
OATP1B3 is a membrane transporter with 12 transmembrane domains.  It is expressed at the 
basolateral membrane of human hepatocytes.  Along with other transporters, like OATP1B1, 
OCT1 and NTCP, OATP1B3 transports many endogenous compounds and xenobiotics (Stieger 
and Hagenbuch, 2014).  Well-known OATP1B3 substrates include unconjugated and conjugated 
bile acids, estradiol conjugates, and drugs like statins and digoxin (Roth et al., 2012).  Because of 
the broad spectrum of structurally-independent substrates, many efforts have been made to 
identify a pharmacophore of OATP1B3.  The Mizuguchi group generated the first 3D model of 
OATP1B3, based on which they hypothesized a central pseudo twofold symmetry axis, 
perpendicular to the membrane plane and a central pore in OATP1B3 (Meier-Abt et al., 2005).  
The central pore was proposed to consist of helices 1, 2 4, 5, 7, 8, 10 and 11.  After that, further 
studies of the OATP1B3 binding pockets have been performed to investigate the structure 
function relationship of OATP1B3.  For example, by site-directed mutagenesis, the positively 
charged amino acids, K41 and R580 in the predicted central pore have been identified as 
important amino acids to maintain the function of OATP1B3 (Glaeser et al., 2010; Weaver and 
Hagenbuch, 2010).  Similar studies revealed that R57, K361 and R580 in OATP1B1 are part of 
the translocation pathway (Weaver and Hagenbuch, 2010). However, several studies with 
different OATPs suggested that the binding sites for different substrates may overlap with each 
other and not be identical (Sugiyama et al., 2002; Grube et al., 2006; Noe et al., 2007; Gui et al., 
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2010), which makes the identification of the binding sites and translocation pathways 
challenging. 
Photoaffinity labeling is a technique first applied in the early 1960s (Singh et al., 1962).  When it 
was developed, it was a powerful tool to study the protein-ligand binding.  This technique is 
based on a photoreactive moiety that is either part of the ligand or attached to it.  The labelled 
ligand will only be activated upon exposure to a certain wavelength of light, and form a highly 
active intermediate, which can bind to any amino acid near it (Hashimoto and Hatanaka, 2008).  
Thus, the binding between protein and ligand is a covalent bond, which allows harsh conditions 
during the purification/analysis.  With the improvement of modern techniques, photoaffinity 
labeling has been widely used in the study of protein-protein, protein-nucleotide and protein-
small molecule interaction (Smith and Collins, 2015).  In combination with LC-MS technologies, 
photoaffinity labeling can be used to identify the ligand binding sites of proteins (Robinette et al., 
2006).  Over the last 3 decades, photoaffinity labeling combined with MS spectrometry has been 
applied to study several transporters.  For example, the rabbit ileal Na+-dependent bile acid 
transporter (IBAT) was identified and characterized using photoaffinity labeling of rabbit brush 
border membrane vesicles (Kramer et al., 1993).  The same group later used a radioactive 
diazirine-labeled bile acid derivative to characterize the substrate binding site of this transporter 
(Kramer et al., 1997; Kramer et al., 2001b).  The binding pockets of P-glycoprotein (Pgp) were 
also investigated by a series of studies using photoaffinity labeling (Morris et al., 1994; Safa, 
2004; Chanmahasathien et al., 2011).  By mutating the binding sites proposed by photoaffinity 
labeling, the mechanism of drug resistance effect of Pgp was investigated, and a pharmacophore 
was proposed based on these studies (Pajeva and Wiese, 2002; Pleban et al., 2005; Globisch et 
al., 2008).   
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Based on this information, we hypothesized that by using photoaffinity labeling technology, the 





2.1 8-Fluorescein-cAMP (8-FcA) is a substrate of OATP1B3 
8-Fluorescein-cAMP (8-FcA) (Figure 5-1) is a substrate of OATP1B3 (Bednarczyk, 2010). 8-
FcA was also used as a photoreactive compound in the study of cGMP-dependent signaling 
pathways in bovine sperm (Borchert, 2005).  
 
 




To confirm 8-FcA as a substrate of OATP1B3 in our cell system, uptake of 8-FcA was measured 
at different time points in wild-type, OATP1B1, or OATP1B3 stable transfected CHO cells.  The 
result showed that 8-FcA is a potent substrate of OATP1B3, with a linear uptake up to 10 mins 
(Figure 5-2A).  After that, the kinetics of 8-FcA uptake by OATP1B3 were also characterized, to 
determine a suitable concentration for the labelling studies (Figure 5-2B).  The result suggested a 
Km value of 2.3 μM, which is comparable to the published Km of 1.8 μM (Bednarczyk, 2010), and 
therefore we used 5 μM 8-FcA for the following studies.  According to a literature search, at least 
three different uptake buffers were used for transporter-related photoaffinity labeling experiments 
(A-Cl, KRH1, and KRH2; Table 2-2) (Middendorff et al., 2002; Lapinsky et al., 2009), and a 
comparison of these buffers with our regular uptake buffer was done to confirm transport activity 
under different buffer systems.  The results shown in Figure 5-2C demonstrate that the uptake of 
8-FcA with the A-Cl buffer showed slightly better signals compared to the other buffer systems.  
Besides that, the A-Cl buffer was also originally used for the photoaffinity labeling of 8-FcA 
(Borchert, 2005).  Based on these findings, the A-Cl buffer was used for the photoaffinity 







18Figure 5-2: Characterization of 8-FcA as a substrate of OATP1B3. 
(A) Uptake of 5 μM 8-FcA was measured at 37 °C with wild-type (closed triangles), OATP1B1 
(open circles) or OATP1B3 (closed circles) expressing CHO cells on 96-well plates.  Values are 
means ± SD of quadruplicate determinations in a single experiment.  (B) Kinetics of 8-FcA was 
measured at 37 °C for 10 minutes with wild-type and OATP1B3 expressing CHO Flp-In cells on 
24-well plates.  The uptake by wild-type cells was subtracted from OATP1B3 expressing cells.  
Values are means ± SD of triplicate determinations in a single experiment.  (C)  Uptake of 1 μM 
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8-FcA was measured at 37 °C for 2 mins with wild-type and OATP1B3 expressing CHO Flp-In 
cells on 24 well plates.  Values are means ± SD of triplicate determinations in a single 
experiment. 
 
2.2 Labeling with fluorescein-cAMP 
To test the hypothesis that 8-FcA can be used to label OATP1B3 in live cells, a time dependent 
labeling experiment was performed first.  CHO Flp-In cells stably expressing OATP1B3-His 
were plated in 10 cm dishes. Once confluent, they were incubated with 5 μM 8-FcA.  
Immediately after the 8-FcA solution was added to the cells, a 302 nm wavelength UV light was 
used to activate 8-FcA for 3, 6, 9 or 12 mins.  The cells were then washed with ice-cold PBS to 
remove the unbound 8-FcA and the labeling was stopped.  Membrane proteins were then 
extracted from the cells and used for immunoblotting.  The western blot probed with an anti-
fluorescein antibody (Figure 5-3A) showed that with increasing time of UV exposure, the binding 
of 8-FcA to proteins increased up to 9 minutes.  However, at 12 minutes exposure, the signals 
decreased, which may be due to the internalization or degradation of proteins after UV exposure.  
Therefore, we selected 6 minutes of UV exposure for the following studies.  The photoaffinity 
labeling experiments were performed in both OATP1B3-expressing CHO Flp-In cells and wild-
type control CHO Flp-In cells.  Losartan, a substrate and strong inhibitor of OATP1B3, was used 
to compete for the binding of 8-FcA.  The western blot result showed that in both cell types, 8-
FcA labeled many proteins with or without UV activation (Figure 5-3B).  However, when cells 
were co-incubated with 8-FcA and 100 μM losartan, the signals obtained with the anti-fluorescein 






19Figure 5-3:  Photoaffinity labeling of OATP1B3 by 8-fluorescein-cAMP. 
(A) Photoaffinity labeling of 5 μM 8-FcA was performed with 3, 6, 9 and 12 minutes exposure to 
UV light at a wavelength of 302nm with OATP1B3 expressing CHO Flp-In cells.  (B) 
Photoaffinity labeling with 5 μM 8-FcA with 6 minutes UV exposure in the presence or absence 
of 100 μM losartan of empty vector or OATP1B3 expressing CHO Flp-In cells.   Membrane 
fractions were extracted and separated by SDS-PAGE.  Anti-fluorescein antibody was used for 





2.3 Purification of OATP1B3 
Based on the high background observed in the 8-FcA labeling experiments, we concluded that a 
good method to purify OATP1B3 was required after labeling.  Since OATP1B3 stably expressed 
in CHO Flp-In cells has a His tag at the C-terminal end, a Ni-NTA column was used initially to 
purify the OATP1B3-His from membrane proteins.  Solubilized membrane proteins were loaded 
on the Ni-NTA column and eluted with 50mM imidazole.  Then, each fraction was separated by 
SDS-PAGE and His-tagged proteins were detected with an anti-His antibody on a western blot 
(Figure 5-4A).  Although OATP1B3-His bound to the column efficiently, it was washed off at a 
low imidazole concentration (50 mM, compare to recommended 200 mM).  This low binding 
affinity led to a poor purity of OATP1B3 in the eluted fractions (Data not shown).  Therefore, we 
tested purification of OATP1B3-His by immunoprecipitation.  To increase the expression of 
OATP1B3, instead of using CHO Flp-In cells, HEK293 cells were transiently transfected with 
empty vector or OATP1B3-His.  Membrane proteins were extracted and solubilized with 0.1% 
NP-40, and then immunoprecipitated with anti-His antibody and magnetic protein G beads.  The 
silver stained gel shown in Figure 5-4B demonstrates that after immunoprecipitation, the purity of 
OATP1B3 is relatively high, and the other proteins detected in the eluted fraction can be cut off 
without affecting the OATP1B3 band.  However, the yield of immunoprecipitation was low and 






20Figure 5-4: Purification of OATP1B3.   
(A) Membrane proteins from OATP1B3 expressing CHO Flp-In cells were solubilized in lysis 
buffer containing 1% Triton X-100, and purified with Ni-NTA columns.  After loading, the 
columns were washed with lysis buffer containing 20 mM imidazole and OATP1B3 was eluted 
with lysis buffer containing 50mM imidazole 5 times.  Fractions were detected with Anti-His 
antibody on western blot.  (B)  Membrane proteins from empty vector or OATP1B3-His 
transiently transfected HEK293 cells in a full 10 cm dish were solubilized in PBS contain 0.1% 
NP-40.  Immunoprecipitation was performed with 2 μg Anti-His antibody and 100 μL magnetic 





In the present study, we confirmed that in our expression system the photoreactive compound, 8-
fluorescein-cAMP indeed is a substrate of OATP1B3 and therefore might be used for 
photoaffinity labeling of OATP1B3.  However, we do not know whether specific labeling of 
OATP1B3 is possible because of the significant background labeling.  We then tried to purify 
OATP1B3 to improve the chances for successful labeling of OATP1B3.  Unfortunately, although 
a small amount of OATP1B3 can be pulled down by immunoprecipitation, the efficiency of the 
pull-down experiment was not high enough for follow-up labeling steps. 
Although the major aim of this study was not completed, several conclusions can be drawn and 
improvements can be suggested for future experiments.  First of all, the increasing signals in the 
time dependency for the photoaffinity experiments suggest that the protocol for photoaffinity 
labeling on live cells works.  However, 8-FcA also bound non-specifically to many other proteins 
even without UV activation (Figure 5-3B). This suggests that 8-FcA may not be stable enough 
under normal condition and therefore most likely is not suitable for these experiments with 
OATP1B3.  The application of photoaffinity labeling with live cells is usually aimed at finding 
potential targets for photoreactive compounds, and since cAMP is a highly reactive substrate for 
many cell signaling pathways (Yan et al., 2016), it is expected to interact with a lot of different 
proteins inside and outside the cells.  Although co-incubation with losartan decreased 8-FcA 
labeling (Figure 5-3B), it is likely that this effect was due to unspecific quenching in the presence 
of this high concentration of losartan.  Other photolabile substrates which are more stable before 
UV activation should be tested with the same or a very similar labeling protocol. 
We have compared several different affinity purification methods to improve the efficiency of 
OATP1B3 pull-down.  His-tagged OATP1B3 can be isolated using Ni-NTA columns. However, 
the interaction between the His tag and the column beads was not strong enough and resulted in a 
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high background binding.  When the Ni-NTA beads were washed with increasing imidazole-
containing elution buffer, OATP1B3-His was eluted off in the fraction with a rather low 
imidazole concentration (50mM), which resulted in a very low purity of OATP1B3.  In the 
experiments shown in Figure 5-4A the membrane proteins were solubilized with 1% TX-100. 
However, lower concentrations and milder types of detergent, including Tween 20 and NP40, 
were also tested to increase the binding strength between OATP1B3-His and the Ni-NTA 
column.  No significant difference was observed.  Immunoprecipitation of wild-type OATP1B3, 
i.e. without a His tag, with a specific polyclonal antibody recognizing OATP1B3, significantly 
increased the purity but also affected the efficiency in a negative way.  The immunoprecipitation 
assays described in this chapter were performed by first incubating the extracted proteins with the 
antibody and then adding protein G.  This order of combining antibody first can enhance the 
binding between OATP1B3 and the antibody, but the binding between the relative large 
complexes of OATP1B3 and antibody with protein G beads will be competed for by free 
antibodies in the solution.  To avoid this competition and to improve the efficiency, antibody 
conjugated protein G beads should be generated first and the extracted proteins should be added 
later to the pre-formed antibody-protein G mix. 
In conclusion, the present study confirmed that fluorescein-cAMP is a substrate of OATP1B3 and 
that it can be activated by UV light.  Purification of OATP1B3 should be possible, but 






Summary and overall discussion 
Drug transporters at the basolateral membrane of human hepatocytes form an efficient but 
complex system to take up endogenous compounds and xenobiotics into the liver.  Some of these 
transporters, like OATP1B1, OATP1B3, OCT1 and NTCP, are listed in the FDA drafted 
guideline for industry and are suggested to be tested for potential DDIs (International Transporter 
et al., 2010).  OATP1B3, as an important member of this uptake system, has a broad spectrum of 
structurally independent substrates, including both conjugated and unconjugated bile acids, 
hormones and drugs like statins, anti-hypertensives and antibiotics (Stieger and Hagenbuch, 
2014).  Among them, only a small portion of the substrates are transported selectively by 
OATP1B3, for example, CCK-8 and telmisartan (Roth et al., 2012; Zhu et al., 2014), while most 
of the substrates are shared by other transporters from different families. This makes the in vivo 
study of individual transporters challenging.  Even knocking out a single transporter in a mouse 
model might not yield the desired results because other transporters expressed in the same cells 
could compensate for the lost function. Therefore, in the case of OATPs the Schinkel group 
knocked out a large cluster of DNA that contains the genes for Slco1a1, Slco1a3, Slco1a4, 
Slco1a5, Slco1a6, and Slco1b2 encoding OATP1A1, OATP1A4 and OATP1B2 that are 
expressed in hepatocytes (van de Steeg et al., 2012). A humanized OATP1B1/3 mouse model has 
been generated based on this cluster knockout mouse and has facilitated the study of the 
contribution of OATP1B1 and/or OATP1B3 to the pharmacokinetics of statins and antitumor 
drugs (Salphati et al., 2014; Durmus et al., 2016).    
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Currently, transporters are typically characterized using cell-based assays. A single transporter 
expressing cell line is constructed and uptake experiments are performed to demonstrate the 
function of the expressed transporter (De Bruyn et al., 2013; Bednarczyk and Boiselle, 2015; 
Zhao et al., 2015).  This is an efficient method to determine the substrates or stimulators of 
transporters, and it can provide information for drug development.  For example, the DDIs 
between grape fruit juice and fexofenadine were discovered using such cell models and the results 
eventually influenced the clinical use (Dresser et al., 2002; Bailey, 2010).  However, the results 
generated by using an isolated in vitro study may not always reflect the situation in vivo.  To 
better predict the in vivo conditions, more complex cell models are required.  Studies have shown 
that some of the drug transporters at the basolateral membrane of human hepatocytes can form 
homo-oligomers, including OATP1B1, OCT1, OAT1 and NTCP (Keller et al., 2008; Duan et al., 
2011b; Bijsmans et al., 2012; Ni et al., 2017).  However, it seems that most of the interactions 
between themselves do not lead to any functional consequences.  In contrast to the homo-
oligomerization of these transporters, little was known regarding the co-expression of drug 
transporters and the functional consequences prior to this dissertation.  With this background, we 
investigated the homo- and hetero-oligomerization of OATP1B3 and its potential consequences 
in the first and second part of this dissertation. 
Besides the oligomerization status, the study of structure function relationship of OATP1B3 can 
also help understanding the mechanism of transport and predicting potential substrates and DDIs 
of OATP1B3.  Photoaffinity labeling is a technique which has been previously used to determine 
the binding and regulatory sites of other transporters, including Pgp (Safa, 2004).  With the 
development of HPLC and MS, the analysis after the photoaffinity labeling can be even more 
precise and in depth (Robinette et al., 2006).  Photoaffinity labeling in conjunction with LC/MS 
analysis can rapidly reveal the accurate binding sites of ligands to the receptors.  After labeling, 
subsequent proteolytic digestion of labelled protein and MS-based sequencing can identify the 
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ligand-binding region and provide valuable information regarding the structure function 
relationship.  In support of the structure function relationship results generated by photoaffinity 
labeling, a general pharmacophore for  Pgp was proposed (Pajeva and Wiese, 2002), which 
facilitated drug design and development by providing potential markers as Pgp substrates  (Li et 
al., 2007).  Using 8-fluorescein-cAMP, we tried to investigate the binding sites and translocation 
pathways of OATP1B3 by using the photoaffinity labeling technique in Chapter 5. 
In Chapter 3, I evaluated the hypothesis that OATP1B3 can form homo-oligomers, and that the 
interaction of OATP1B3 with itself may lead to functional consequences.  Drug transporters such 
as OATP1B1, OCT1, OAT1 and NTCP can all form homo-oligomers, which suggested that 
OATP1B3 likely can also interact with itself.  As demonstrated in Chapter 3, OATP1B3 indeed 
can form homo-oligomers, and we proved it with several lines of evidence.  Co-
immunoprecipitation experiments confirmed a physical interaction between the His- and the 
FLAG-tagged OATP1B3, while the PLA demonstrated the close association between the two 
differently tagged OATP1B3.  Interestingly, I also observed an interaction between the His- and 
the HA-tagged OATP1B3, although the C-terminal end of OATP1B3-HA, unlike wild-type or 
His-tagged OATP1B3, is accessible at the extracellular side of the membrane. This result 
suggested that the C-terminal end of OATP1B3 is not exclusively involved in the interaction.  
Then, I investigated the consequences of OATP1B3 homo-oligomers, by co-expressing wildtype 
OATP1B3 with a non-functional mutant OATP1B3.  Two transporter models have been proposed 
by the van de Graaf group for NTCP homo-oligomers (Bijsmans et al., 2012).  In the first one the 
subunits in the oligomers work as one functional unit, so a mutant subunit would completely 
block the function of this oligomer.  In the other model the subunits in the oligomers work as 
individual functional units and a mutant subunit would not influence the other subunits.  My 
results demonstrated that the individual subunits work independently from each other and thus the 
functional unit model is the transport model for OATP1B3 homo-oligomers. This suggested that 
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the homo-oligomerization does not influence the function of OATP1B3.  Though the mechanism 
of oligomerization is not the focus of this dissertation, a recent study of OATP1B1 homo-
oligomerization may give some suggestions for OATP1B3 homo-oligomers (Ni et al., 2017).  
This study demonstrated that the three GXXXG motifs in OATP1B1 are involved in the function 
or formation of homo-oligomers. Because the three motifs are completely conserved in 
OATP1B3 it is well possible that they are involved in the oligomerization. 
Since many of the transporters expressed at the basolateral membrane of human hepatocytes can 
form homo-oligomers and NTCP can also interact with other transporters in the SLC10 family 
(Bijsmans et al., 2012), we speculated that uptake transporters in hepatocytes could be co-
localized in the same membrane micro-domains and their interactions  could lead to functional 
consequences.  In Chapters 3 and 4 I investigated part of this hypothesis by focusing at the 
hetero-oligomerization of OATP1B3 and its functional consequences.  As a starting point, a 
DUALmembrane screening using OATP1B3 as a bait was performed to investigate potential 
interaction partners.  The DUALmembrane screening is a modified yeast two hybrid screening 
assay designed for detecting the interaction between membrane proteins.  Instead of using a 
soluble fraction of membrane proteins for the regular yeast two hybrid screening, the 
DUALmembrane screening can use the full-length, membrane-anchored protein as the bait.  By 
using this screening method, OCT1 was suggested to have the highest potential as an interaction 
partner of OATP1B3.  I then demonstrated the interaction of OATP1B3 and OCT1 by performing 
co-immunoprecipitation experiments using primary human hepatocytes as the starting material.  
After that, HEK293 cells were used as a cell-based model to further study interactions between 
OATP1B3 and other transporters.  The Proximity Ligation Assay showed that OATP1B3 can 
interact not only with OCT1, but also with OATP1B1 and NTCP. In addition, I could further 
verify the interaction with OCT1 and NTCP in frozen human liver sections.  However, because of 
the lack of a pair of OATP1B1 and OATP1B3 specific antibodies from two different species, the 
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interaction between OATP1B3 and OATP1B1 could not be studied in frozen liver sections.  The 
observed interaction between OATP1B3 and OCT1 or NTCP in frozen liver section supported the 
hypothesis that there are transporter micro domains in the basolateral membrane of human 
hepatocytes.  To investigate this hypothesis, co-localization of these transporters with lipid raft 
markers like caveolins should be investigated. 
I then wanted to study the influence of the hetero-oligomerization on function by measuring the 
uptake of model substrate of both OATP1B3 and the respective interacting transporters.  The 
results showed that when co-expressed with OATP1B3, there is no functional effect on OCT1, 
OATP1B1 and NTCP.  However, OATP1B3 is affected in a transporter-dependent way.  When 
co-expressed in HEK293 cells with OCT1, the uptake of the OATP1B3 model substrate CCK-8 
decreased significantly, but was not affected when OATP1B3 was co-expressed with OATP1B1 
or NTCP.  I also performed surface biotinylation experiments to determine the surface expression 
change due to the co-expression.  Interestingly, although there is no effect on the expression level 
of the interacting transporter, the OATP1B3 expression level is affected by co-expression in a 
transporter-dependent way.  When co-expressed with OCT1, the plasma membrane expression of 
OATP1B3 decreased dramatically, while co-expression with OATP1B1 or NTCP led to an 
increase of OATP1B3 surface expression.   I then normalized the uptake result based on surface 
expression and the apparent decrease of OATP1B3 function due to the OCT1 interaction was 
actually a stimulation while interaction with OATP1B1 and NTCP led to a reduction of 
OATP1B3 function.  Normalized kinetics suggested that modulation of OATP1B3 uptake by 
OCT1 only changed the Vmax but not the Km of CCK-8 uptake, which suggested that 
oligomerization affected the turnover rate.  Interactions with OATP1B1 or NTCP however, 
affected both the Km and the Vmax values. These results showed that the interacting partners can 
influence both the expression and function of OATP1B3, in a transporter-dependent way.  
Although no direct in vivo result can prove my findings under normal physiological condition, the 
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corresponding transporters in mice, mouse OATP1B2 and mouse OCT1, showed a similar 
pattern.  In the mouse model of nonalcoholic steatohepatitis (NASH), the mouse OATP1B2 was 
down-regulated while the mouse OCT1 expression level went up (Clarke et al., 2014a; Clarke et 
al., 2015).  To test this hypothesis, the OCT1 knockout mouse model could be used to investigate 
the potential expression level change of OATP1B2.  Pharmacokinetic parameters of an 
OATP1B2 specific substrate should be collected from both wild-type and OCT1 knockout mice, 
which could demonstrate a potential functional influence of OCT1 for OATP1B2 function in 
vivo. 
Combining the findings from these two chapters, we can conclude that OATP1B3 can from 
homo- and hetero-oligomers, and that the hetero-oligomerization of OATP1B3 with OCT1, 
OATP1B1 and NTCP can lead to changes in expression and function.  There are several potential 
physiological and pharmacological implications of these findings. First, these results could be 
explained by assuming that the drug transporters at the basolateral membrane of human 
hepatocytes are co-localized in the same micro domains.  Some transporters expressed in other 
membranes are co-localized in membrane micro domains.  For example, in the endothelial cells 
of the blood brain barrier, Pgp is localized in caveolae and can interact with caveolin-1(Jodoin et 
al., 2003).  Rat MRP2 also co-localizes with caveolin-1 in the canalicular membrane of rat 
hepatocytes (Ismair et al., 2009).  Therefore, transporters expressed at the basolateral membrane 
of human hepatocytes could also be expressed in the same micro domain and be regulated 
together.  Second, the co-localization of OATP1B3 and OATP1B1, NTCP, and OCT1 and 
potentially other transporters could lead to a change of the micro environment and influence the 
function of certain transporters.  For example, most OATPs work better at an acidic pH (Leuthold 
et al., 2009) but the plasma pH in the liver is at 7.3-7.4 which would not affect OATP function. 
However, if an OATP would be co-localized with the Na+/H+ exchanger or other proton extruding 
transporters or pumps, the local environment could become more acidic and could enhance the 
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transport activity of OATPs.  Third, the change in OATP1B3 plasma membrane expression, when 
co-expressed with OCT1, OATP1B1 or NTCP suggests a post-translational modulation.  Unlike 
OATP1B1 and NTCP who are evenly distributed throughout the liver lobule, expression of 
OATP1B3 is lowest around the portal field (zone 1) and increases toward the central vein (zone 
3) (König et al., 2000).  Although the lobular distribution of human OCT1 is not clear, the 
expression of mouse OCT1 also increases toward the central vein (Chen et al., 2014). Assuming 
that the situation is similar in human liver this might explain the difference in the effects of co-
expression of OATP1B3 with OCT1 as compared to OATP1B1 and NTCP.  To investigate this 
hypothesis, the lobular distribution of mouse OATP1B2 needs to be compared between wild-type 
and OCT1 knockout mice and the same comparison could be performed with NTCP knockout 
mice.  Last but not least, the significant modulation of OATP1B3 transport activity when co-
expressed with OCT1, OATP1B1 and NTCP suggests that the in vitro - in vivo extrapolation of 
transporter activity could be misleading.  The effects of a certain transporter to the 
pharmacokinetic parameters of a drug is usually extrapolated from Km and Vmax values that are 
obtained from cell-based uptake assays, which are normally conducted using cell lines expressing 
a single transporter.  If my findings indeed represent the in vivo situation, then cell lines 
expressing single transporters over- or underestimate Vmax values, which can result in dramatic 
differences of the pharmacokinetics parameters. Thus, in the future co-expression systems might 
have to be used to get better predictions. 
In chapter 5, the hypothesis that photoaffinity labeling can be used to investigate the binding 
pocket and translocation pathways of OATP1B3 was not successfully tested because of the 
technical problems I encountered.  Before a proteomics mass spectrometry approach can be used 
to verify the binding of a photolabile compound, purified OATP1B3 in high microgram quantities 
need to be isolated.  By using immunoprecipitation, I was able to pull down OATP1B3 with high 
purity, but the efficiency was not high enough to generate enough material for the follow-up 
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analysis.  One reason for this problem is that the detergent serves as a double-edged sword in this 
case.  As a highly hydrophobic transmembrane protein, the solubilization of OATP1B3 requires 
the help of detergents. However, a high concentration of detergent can significantly reduce the 
antigen-antibody binding efficiency required for immunoprecipitation.  To find a balanced type 
and concentration of detergent is very time consuming.  Unfortunately, time for my study was 
running out. I tested several detergents, including TX-100, Tween 20 and NP40, at a variety of 
concentrations. Although I was able to pull down a small amount of OATP1B3 in the presence of 
0.1% NP-40, I lost most of the protein during solubilization and immunoprecipitation.  There are 
several directions that should be followed up to improve the efficiency of purification.  First of 
all, other non-ionic detergents need to be tested.  Typically, a detergent with a higher critical 
micelle concentration (CMC) can solubilize more membrane protein, but a detergent with a lower 
CMC can minimize the influence to the antibody-antigen complex formation and thus increase 
the pull down efficiency.  Second, a suitable epitope can be added to the protein to increase the 
strength of the antibody-antigen interaction.  Although several copies of tags, for example two or 
three His tags at the C-terminal end, can increase the binding affinity, the structural and 
functional consequences introduced by the larger size and more significantly the electrochemical 
properties might become a problem.  Besides that, the ratio between antibody and amount of 
solubilized protein can also influence the pull-down efficiency.  Overloading the assay with free 
antibody can reduce the efficiency because these unused antibodies can compete for agarose-
protein G with the antibody-antigen complexes, while overloading the assay with solubilized 
protein can increase the non-specific binding. 
 
Overall, in this dissertation, I investigated the oligomerization of OATP1B3 and its potential 
consequences.  First, I demonstrated that OATP1B3 can form homo-oligomers in HEK293 cells.  
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The follow-up studies showed that the subunits in the homo-oligomers worked as individual 
functional units.  Then, I also demonstrated that OATP1B3 can interact with OCT1, OATP1B1 
and NTCP in HEK293 cells, and further verified the interaction between OATP1B3 with OCT1 
and NTCP in frozen human liver sections.  The functional consequences have also been studied in 
HEK293 cells and showed a transporter-dependent effect on both, expression and function of 
OATP1B3, but not on the other interacting transporters.  Based on my findings, I proposed that 
the current single transporter expressing cell model may lead to incorrect in vitro to in vivo 
extrapolation, and that a multi-transporter expression system may better mimic the normal 
physiological basolateral membrane of human hepatocytes.  In addition, I established a 
preliminary method for the purification of OATP1B3.  However, the method still requires a lot of 






In general, the study of liver drug transporters is challenging, especially in vivo studies, because 
of the overlapping substrate and inhibitor specificity among the different transporters.  Though 
some human transgenic mice or single transporter knockout mouse models were generated (van 
de Steeg et al., 2013; Chen et al., 2014), there are still limitations.  The most significant 
shortcoming is the redundancy of several transporters for one compound which can compensate 
the effects of knockout or knockin of a specific transporter (Cheng et al., 2016).  Besides that, 
murine hepatic transporters like OATP1A1, OATP1A4 and OATP1B2 are not orthologs of 
individual human liver transporters like OATP1B1 and OATP1B3.  There is no OATP1A family 
member expressed under normal conditions in human hepatocytes but there are two members in 
mouse liver. Similarly, the two human OATP1B1 and OATP1B3 have only a single mouse 
ortholog, OATP1B2 (Hagenbuch and Meier, 2004). Thus, the distribution and function of these 
transporters cannot clearly be correlated to each other between the two species.  Because of these 
difficulties of using small animal models, cell-based studies have been developed to determine 
the function or individual function of specific transporters (Cheng et al., 2016).  However, similar 
to all other in vitro studies, although the cell-based assays provide excellent data for each 
transporter, the respective transport activity in vivo remains unknown.  As a consequence, the in 
vitro to in vivo extrapolation which plays a key role in clinical transporter studies can sometimes 
be proven wrong (Cheng et al., 2016), which suggests that the cell model may not reliably reflect 
the physiological condition.  In this dissertation, I investigated and discussed the homo- and 
hetero-oligomerization of OATP1B3 and its functional consequences.  Based on my findings, it 
may be necessary to consider the functional variations due to the interactions among transporters 
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when extrapolating from in vitro to in vivo models.  To better address these potential 
consequences for extrapolations, several directions could be taken based on this dissertation. 
For the homo-oligomerization of OATP1B3, I showed the formation and functional model of 
OATP1B3 homo-oligomers.  However, the mechanism of oligomerization was not investigated.  
Other homo-oligomerization studies of transporters, including OATP1B1 (Ni et al., 2017) and 
OAT1 (Duan et al., 2011b), suggested that the GXXXG motifs could affect the formation of 
oligomers or the function of transporters.  It is well possible that OATP1B3 shares the same 
mechanism, since the GXXXG motifs in OATP1B1 are completely conserved in OATP1B3.   To 
study a possible involvement of a GXXXG motif for OATP1B3 oligomerization, site-directed 
mutagenesis of the different GXXXG motifs could be performed.  Since GXXXG motifs have 
been proven to be involved in both correct oligomerization and protein folding of many 
transmembrane proteins (Teese and Langosch, 2015), several outcomes of these experiments are 
expected.  The first potential outcome is that the surface expression of mutant OATP1B3 remains 
the same but the oligomerization is affected.  This outcome would show that the mutated 
GXXXG motif is involved in the process of OATP1B3 oligomerization.  Another potential 
outcome is that the surface expression of OATP1B3 is either increased or decreased.  After 
normalization for surface-expressed OATP1B3, the effect on oligomerization of OATP1B3 by 
the mutated GXXXG could then be measured.  However, if no effect on OATP1B3 surface 
expression and oligomerization can be observed after site-directed mutagenesis of GXXXG 
motifs, several other motifs or amino acids could be investigated to at least find residues 
important for oligomerization, including (small)XXX(small) motifs in the TMD, or cysteines in 
the ECL.  Once the mechanism of OATP1B3 homo-oligomerization is understood, we can further 
manipulate the formation of OATP1B3 oligomers to study the functional influence of 
oligomerization.  For example, comparison of the expression and function between oligomerized 
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and individual OATP1B3 proteins could explain the cooperative effects when oligomers are 
formed. 
The study of hetero-oligomerization of OATP1B3 was the primary focus of this dissertation.  
However, several questions remain unsolved.  For example, the interaction between OATP1B1 
and OATP1B3 could so far not be confirmed in frozen liver sections because no suitable 
OATP1B1 and OATP1B3 specific antibodies are available.  Since a rabbit OATP1B3 specific 
antibody is available in our lab, the problem can be solved by generating a monoclonal OATP1B1 
specific antibody.  As an alternative to the conventional production of monoclonal antibodies, 
antibody Phage display technology could be used.  By screening a library of bacteriophages 
expressing a variable chain with cells expressing the target protein (OATP1B1) and with wild 
type cells, the phages expressing a specific variable chain could be selected.  After panning and 
extracting, the corresponding plasmid for this variable chain can then be purified and used right 
away or the specific variable chain could be inserted into a full-length antibody plasmid and 
expressed by bacteria. 
The functional consequences of hetero-oligomerizations need to be further investigated in 
primary human hepatocytes by knocking out the interacting partners.  Based on the findings in 
this dissertation, that the presence of OCT1 reduces the apparent uptake function of OATP1B3, 
knocking out OCT1 in human hepatocyte should stimulate the uptake of CCK-8 by OATP1B3. 
Although studies have shown that during the in vitro cultivation of human hepatocytes the uptake 
function of OATP1B3 increased (Zhu et al., 2014), it is not known how OCT1 function changes 
and whether it would affect OATP1B3, but it is well possible that the gain of OATP1B3 function 
is due to the loss of OCT1.  To test this hypothesis, scrambled siRNA and OCT1 specific siRNA 
should be transfected into human hepatocytes.  The expression level and function of OCT1 and 
OATP1B3 could then be monitored by performing uptake assays with their specific substrates 
100 
 
like MPP and CCK-8.  If the functional consequences demonstrated in vitro indeed would be 
recapitulated in vivo, an increase of OATP1B3 function should be correlated with the decrease of 
OCT1 function.  Besides that, to generate a reliable hetero-oligomerization cell model for 
functional studies that resembles more the normal physiological conditions, the ratio of 
OATP1B3 and its interacting partners need to be adjusted.  Preliminary data from our lab 
suggested that the ratio of surface-expressed OATP1B3 and OCT1 can be adjusted based on the 
ratio of respective plasmids transfected into the HEK293 cells.  Combined with the published 
data of OATP1B3 and OCT1 expression ratio in human hepatocytes (Peng et al., 2015), different 
ratios of OATP1B3 and OCT1 plasmids can be co-transfected into cells, and have to be followed 
up with mass spectrometry to determine the respective protein quantities.  After adjustments 
according to the expression levels, a cell model with an accurate ratio between OATP1B3 and 
OCT1 should be achieved.  Functionally, interactions between OATP1B3 and its partners can 
lead to a change in transport activity by altering the turnover rate of OATP1B3. Our findings that 
indeed the Vmax was increased after correction of surface expression clearly demonstrates that the 
interaction itself can lead to functional consequences.  However, it is well possible that the 
transport activity of OATP1B3 can be affected by the functional change of interacting partners, 
such as activation, inhibition and mutation.  This hypothesis can be investigated by treating the 
co-expressing cells with OATP1B3 substrates in the presence or absence of specific substrates or 
inhibitors for the interacting partners.  For example, uptake of CCK-8 could be measured in cells 
expressing OATP1B3 in the presence or absence of OCT1 and treated with or without cimetidine.  
Preliminary data in our lab demonstrated that cimetidine is not an OATP1B3 inhibitor when 
OATP1B3 is expressed in HEK293 cells alone.  However, the outcome of this experiment could 
show that when OCT1 is co-expressed, cimetidine stimulates or inhibits the uptake of CCK-8 by 
OATP1B3 or does not affect it at all. 
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Since the effect of co-expression of OATP1B3 with OCT1, OATP1B1 or NTCP is not the same, 
the interaction among three or even more transporters can be very complex but it is nevertheless 
important to understand it in order to delineate the physiological conditions from a cell model.  
To conclude, a challenging but ideal liver transporter-related cell model should have all human 
hepatic drug transporters expressed at their physiological expression ratios. 
All the experiments and strategies mentioned above will lead to a better understanding of the 
interactions and functional consequences among human hepatic drug transporters, and thus 
contribute to an improved in vitro to in vivo extrapolation.  Eventually these findings should 
allow to improve the physiological-based pharmacokinetic models in predicting transporter-
related effects.    
Though the low efficiency of purification of OATP1B3 has prevented the successful completion 
of the binding site and translocation pathway study, I believe that the photoaffinity labeling is still 
a good method to study the structure function relationship of OATP1B3.  Since the purification of 
OATP1B3 by immunoprecipitation has been proven very challenging, besides optimization of the 
protocol, an alternative way to isolate OATP1B3 should be considered.  For example, two-
dimensional electrophoresis may help to separate the OATP1B3 away from the massive amount 
of other proteins and help to isolate OATP1B3.  During the optimizing of OATP1B3 purification, 
the generation of a radiolabeled or fluorescent photoreactive substrate for OATP1B3 would be 
helpful to develop a good protocol for photoaffinity labeling.  These strategies may allow to 
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